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1. INTRODUCTION 
From decades an acute disease or chronic illness is being clinically treated 
through delivery of drugs to the patients in the form of some pharmaceutical dosage 
forms like tablets, capsules, pills, creams, liquids, ointments, aerosols, injectable and 
suppositories.  Presently, these conventional dosage forms are primarily prescribed 
pharmaceutical products and most of them are available over the counter. 
To achieve and to maintain the concentration of an administered drug within 
therapeutically effective range, it is often necessary to take drug dosage several times 
in a day and this result in a fluctuating drug plasma levels.1   
Oral ingestion is the traditionally preferred route of drug administration, 
providing a convenient method of effectively achieving both local and systemic 
effects. In conventional oral drug delivery systems, there is very little control over 
release of the drug. The effective concentration at the target site can be achieved by 
intermittent administration of grossly excessive doses. Which in most situations, often 
results in constantly changing, unpredictable and often sub-or-supra therapeutic 
plasma concentrations leading to marked side effects.2   
      The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body to achieve promptly and then maintain the desired 
drug concentration. To achieve this goal, it would be advantageous and more 
convenient to maintain a dosing frequency to once, or at most, a twice-daily regimen.  
An appropriately designed extended release dosage form can be a major advance in 
this direction compared to conventional immediate release dosage forms.3 The 
development of improved method of drug delivery has received a lot of attention in 
the last two decades.4,5 
        This technique for the drug administration is termed ‘sustained release’ or 
‘controlled release’. It is based on the concept of implanting into the body, a reservoir 
of a drug contained in a special biodegradable polymeric carrier material.6 The overall 
objective is that, once the drug/carrier material has been injected, or otherwise 
implanted or taken orally into the body, the drug is released at some predetermined 
rate for some desired period of time.7 
Sustained release technology is a relatively new field, and as a consequence, 
research in the field has been extremely fertile and has produced many discoveries. 
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New and more sophisticated sustained release drug delivery system constantly being 
developed and tested.8 
Successful fabrication of sustained release products is usually difficult and 
involves consideration of the physical chemical properties of the drug, 
Pharmacokinetic behavior of drug, route of administration, disease state to be treated 
and most importantly placement of the drug in a dosage form that will provide the 
desired temporal and spatial delivery pattern for the drug.9 
             There are literally dozens of names associated with sustained release products 
such as continuous release, controlled release, delayed release, delayed action, depot, 
extended action, gradual release, long acting, long lasting, long-term release, 
prolonged release, repository retard, slowly acting, slow release, time coat, sustained 
release, sustained action, time disintegration, time release etc.9,10 
Once a day or at the most twice a day formulation is a holy grail of sorts for 
scientists working with oral dosage forms. A sustained release preparation that makes 
once or twice daily administration of drug possible might be an advantageous dosage 
form, especially in long-term therapy.11 
Among various technologies available, monolithic matrices-matrix tablets 
continue to be popular because of simple processing technologies required, 
reproducibility, stability of the materials and dosage form as well as ease of scale-up 
operation.11 In particular, the interest awakened by matrix type deliveries is 
completely justified in view of their biopharmaceutical and pharmacokinetics 
advantages over the conventional dosage forms. These are release systems for delay 
and control release of a drug that is dissolved or dispersed in a resistant support to 
disintegration. During the last two decades swelling polymers are being used as 
sustained or controlled release devices.12 
Matrix tablets are one of the most widely used dosage forms within controlled 
release techniques in pharmaceutical manufacturing standards, as drug release rates 
are controlled mainly by the type and proportion of excipients used in the preparations 
and no complex production procedures such as coating and pelletization are 
required.13 
Matrix devices have a major advantage over other controlled release devices, 
as they cannot undergo sudden dose dumping. This gives a higher initial release rate 
and can be made to release at a nearly constant rate. The polymer when incorporated 
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into pharmaceutical dosage forms such as tablets had shown a tendency to linearise 
the drug release curves and gives zero order release.14 
 
There is a continuously growing interest of the pharmaceutical industry for 
drug delivery in sustained or controlled release form. There is also a high interest for 
dosage formulations allowing high loading, particularly for drugs requiring high 
therapeutic concentrations in circulation. For this purpose, various polymeric systems 
were studied and interesting release kinetics was obtained from pharmaceutical 
dosage forms such as microparticles, nanosphears and microcapsule tablets with high 
loading capacity.  
Analysis of the release data for these forms showed the effects of drug 
solubility and loading as well as the influence of the characteristics of polymer or of 
the other excipients on the release mechanism. There is a need for sustained release 
system to realize formulation with smaller amount of polymeric excipients able to 
control the release of higher amounts of drug from high loading dosages.15 
A wide variety of antimicrobial agents are available to treat established 
infections caused by bacteria, fungi, viruses or parasites.16 The development of 
antimicrobial drugs represents one of the most important advances in therapeutics, 
both in the control or cure of serious infections and in the prevention and treatment of 
infections complications of other therapeutic modalities. 
Antibacterial agents may be classified as bacteristatic or bactericidal. For 
agents that are primarily bacteristatic, inhibitory drug concentrations are much less 
than bactericidal drug concentrations. In general, cell wall-active agents are 
bactericidal and drugs that inhibit protein synthesis are bacteristatic. Bactericidal 
agents should be selected over bacteristatic ones in circumstances in which local or 
systemic host defenses are impaired. Bactericidal agents are required for treatment of 
endocarditis and other endovascular infections, meningitis, urinary tract infections 
and respiratory tract infections.17 
The therapeutic implication of the relationship between the antibacterial 
activity of an antibiotic and its pharmacokinetic profile is not firmly established. The 
minimum inhibitory concentration (MIC) is generally the most common method of 
assessing and comparing antibacterial activity, although it is generally understood that 
there are limitations in extrapolating these values to the in vivo situation. The ability 
of an antibiotic to reach and maintain effective concentrations to the site of infection 
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and interactions at the infection site for an antibiotic are probably dependent on a 
number of physiologic and physiochemical factors. It is generally understood that 
factors including the lipophilicity, size and charge of the cephem molecule may be 
involved in the rate and extent of drug penetration into interstitial fluid. Binding to 
serum protein on various tissue components may also play an important role in the 
activity of these agents. There is a continued debate as to whether high initial and/or 
sustained serum concentrations are necessary for effective antibiotic therapy.18 
For an effective antibacterial therapy, the serum concentrations of an antibiotic 
should persist for a large fraction of the dosing interval and the persistence of 
antibiotic should be equal to or better than that for the other drugs. 
 
1.1. AN OVERVIEW ON SUSTAINED DRUG DELIVERY SYSTEM 
Oral drug delivery has been known for decades as the most widely utilized 
route of administration among all the routes that have been explored for the systemic 
delivery of drugs via various pharmaceutical products of different dosage forms. The 
reason that the oral route achieved such popularity may be in part attributed to its ease 
of administration as well as the traditional belief that by oral administration the drug 
is well absorbed as the food stuffs that are ingested daily. In fact the development of a 
pharmaceutical product for oral delivery, irrespective of its physical form involves 
varying extents of optimization of dosage form characteristics within the inherent 
constraints of GI physiology. Therefore a fundamental understanding of various 
disciplines including GI physiology, pharmacokinetics, pharmacodynamics and 
formulation design are essential to achieve a systemic approach to the successful 
development of an oral pharmaceutical dosage form. 
The more sophisticated a delivery system, the greater is the complexity of 
these various disciplines involved in the design and optimization of the system. In any 
case, the scientific framework required for the successful development of an oral drug 
delivery system consists of a basic understanding of the following three aspects: 
 Physicochemical, pharmacokinetic and pharmacodynamic characteristics of the drug. 
i) The anatomic and physiologic characteristics of the GIT, and 
ii) Physicochemical characteristics and the drug delivery mode of the dosage 
form to be designed.19 
Oral ingestion has long been the most convenient and commonly employed 
route of drug delivery. Indeed, for sustained-release systems, the oral route of 
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administration has by far received the most attention with respect to research on 
physiological and drug constraints as well as design and testing of products. This is 
because there is more flexibility in dosage form design for the oral route than there is 
for the parenteral route.20 
 Over the past 30 years, as the expense and complications involved in 
marketing new drugs entities have increased, with concomitant recognition of the 
therapeutic advantages of controlled drug delivery, greater attention has been focused 
on development of sustained or controlled release drug delivery systems. There are 
several reasons for the attractiveness of these dosage forms. It is generally recognized 
that for many disease states, a substantial number of therapeutically effective 
compounds already exist. The effectiveness of these drugs, however is often limited 
by side effects or the necessity to administer the compound in a clinical setting. The 
goal in designing sustained or controlled-delivery systems is to reduce the frequency 
of dosing or to increase effectiveness of the drug by localization at the site of action, 
reducing the dose required or providing uniform drug delivery.21  
 The enormous problem of patient compliance as well as the therapeutic 
desirability of controlled tissue drug levels over the time course of therapy are 
sufficiently compelling reasons to warrant placement of drugs in a sustained form of 
drug delivery.22  
 In the past, many of the terms used to refer to therapeutic systems of 
controlled and sustained release have been used in an inconsistent and confusing 
manner.22Sustained release, sustained action, prolonged action, controlled release, 
extended action, timed release, depot and repository dosage forms are the terms used 
to identify drug delivery systems that are designed to achieve a prolonged therapeutic 
effect by continuously releasing medication over an extended period of time after 
administration of a single dose.23 
1.2. TYPES OF DRUG RELEASE SYSTEMS 
Modified-release delivery systems may be divided conveniently into four categories:- 
A. Suatained release 
B. Delayed release 
C. Site-specific targeting 
D. Receptor targeting  
Sustained-release systems include any drug-delivery system that achieves slow 
release of drug over an extended period of time. If the systems can provide some 
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control, whether this be of a temporal or spatial nature, or both, of drug release in the 
body, or in other words, the system is successful at maintaining constant drug levels 
in the target tissue or cells, it is considered a controlled-release system.24  
 
Table 01: Classification of sustained/controlled release systems25 
Type of system Rate-control mechanism 
Diffusion controlled 
 Reservoir system 
 Monolithic system 
 
Diffusion through membrane 
Water penetration controlled 
 Osmotic system 
 Swelling system 
- transport of water through semipermeable 
membrane 
- water penetration into glossy polymer 
Chemical controlled 
 Monolithic system 
 Pendant system 
 
 Ion exchange resins 
 
- Surface erosion or bulk erosion 
- Hydrolysis of pendent group and diffusion from 
bulk            polymer 
-Exchange of acidic or basic drugs with the ions  
present on resins. 
Regulated system 
 Magnetic, Ultrasound 
- External application of magnetic field or 
ultrasound to device 
 
A. Sustained release preparations : 
These preparations provide an immediate dose required for the normal 
therapeutic response, followed by the gradual release of drug in amounts sufficient to 
maintain the therapeutic response for a specific extended period of time. 
The major advantage of this category is that, in addition to the convenience of 
reduced frequency of administration, it provides blood levels that are devoid of the 
peak-and-valley effect which are characteristic of the conventional intermittent 
dosage regimen.22 Sustained release dosage forms are designed to complement the 
pharmaceutical activity of the medicament in order to achieve better selectivity and 
longer duration of action.26  
B. Controlled release preparations : 
Although this term has been interchanged widely with sustained release 
preparations in the past, recently it has become customary to restrict the latter term to 
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oral formulations where the mechanism of prolonged action is dependent on one or 
more of the environmental factors in the gastrointestinal tract such as pH, enzymes, 
gastric motility etc. 
On the other hand, the term controlled release dosage form usually applies to 
preparations that are designed for all routes of administration and where the 
mechanism of prolonged action is inherent and determined totally by the delivery 
system itself. Consequently, this category offers the current state-of-the-art products 
where the drug release profile is controlled accurately and often can be targeted to a 
special body site or a particular organ. 
1.2.1.Advantages of Sustained release dosage forms : 
1) Decreased local and systemic side effects: 
- Reduced gastrointestinal irritation. 
2) Better drug utilization: 
- Reduction in total amount of drug used. 
- Minimum drug accumulation on chronic dosing.  
3) Improved efficiency in treatment: 
- Optimized therapy. 
- Reduction in fluctuation of drug level and hence more uniform 
pharmacological response. 
- Special effects e.g. sustained release aspirin provides sufficient drug so 
that on awakening the arthritic patient gets symptomatic relief.  
- Cure or control of condition more promptly. 
- Less reduction in drug activity with chronic use. 
- Method by which sustained release is achieved can improve the 
bioavailability of some drugs e.g. drugs susceptible to enzymatic 
inactivation can be protected by encapsulation in polymer systems 
suitable for sustained release. 
4) Improved patient compliance:  
- Less frequent dosing 
- Reduced night-time dosing 
- Reduced patient care time. 
5) Economy: 
- Although the initial unit cost of sustained release products is usually 
greater than that of conventional dosage forms because of the special 
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nature of these products, the average cost of treatment over an 
extended time period maybe less. Economy may also result from a 
decrease in nursing time and hospitalization time.22 
 
1.2.2.Biological Factors Influencing Oral Sustained-Release Dosage Form Design 
1) Biological half-life : 
 Therapeutic compounds with short half-lives are excellent candidates for 
sustained-release preparations, since this can reduce dosing frequency.  
2) Absorption : 
 The absorption rate constant is an apparent rate constant, and should, in 
actuality, be the release rate constant of the drug from the dosage form. If a drug is 
absorbed by active transport, or transport is limited to a specific region of the 
intestine, sustained-release preparations may be disadvantageous to absorptions.  
3) Metabolism :  
 Drugs that are significantly metabolized before absorption, either in the lumen 
or tissue of the intestine, can show decreased bioavailability from slower-releasing 
dosage forms. Most intestinal wall enzyme systems are saturable. As the drug is 
released at a slower rate to these regions, less total drug is presented to the enzymatic 
process during a specific period, allowing more complete conversion of the drug to its 
metabolite.  
1.2.3. Physicochemical factors influencing oral sustained-release dosage form 
design : 
1) Dose Size : 
 In general, single dose of 0.5 – 1.0 g is considered maximal for a conventional 
dosage form. This also holds true for sustained-release dosage forms. Another 
consideration is the margin of safety involved in administration of large amounts of 
drug with a narrow therapeutic range.  
2) Ionization, pKa and aqueous solubility :  
 Most drugs are weak acids or bases. Since the unchanged form of a drug 
preferentially permeates across lipid membranes, it is important to note the 
relationship between the pKa of the compound and the absorptive environment. 
Delivery systems that are dependent on diffusion or dissolution will likewise be 
dependent on the solubility of drug in the aqueous media. For dissolution or diffusion 
sustaining forms, much of the drug will arrive in the small intestine in solid form, 
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meaning that the solubility of the drug may change several orders of magnitude 
during its release. The lower limit for the solubility of a drug to be formulated in a 
sustained release system has been reported to be 0.1 mg/ml. 
3) Partition coefficient : 
 Compounds with a relatively high partition coefficient are predominantly 
lipid-soluble and, consequently, have very low aqueous solubility. Furthermore these 
compounds can usually persist in the body for long periods, because they can localize 
in the lipid membranes of cells. 
4) Stability :  
 Orally administered drugs can be subjected to both acid-base hydrolysis and 
enzymatic degradation. For drugs that are unstable in the stomach, systems that 
prolong delivery over the entire course of transit in the GI tract are beneficial. 
Compounds that are unstable in the small intestine may demonstrate decreased 
bioavailability when administered from a sustaining dosage form.21 
 
1.3. Drug selection for oral sustained release drug delivery systems17 
The biopharmaceutical evaluation of a drug for potential use in controlled 
release drug delivery system requires knowledge on the absorption mechanism of the 
drug form the G. I. tract, the general absorbability, the drug’s molecular weight, 
solubility at different pH and apparent partition coefficient. 
 
Table 02: Parameters for drug selection 
Parameter Preferred value 
Molecular weight/ size < 1000 
Solubility > 0.1 mg/ml for pH 1 to pH 7.8 
Apparent partition coefficient High 
Absorption mechanism Diffusion 
General absorbability From all GI segments 
Release Should not be influenced by pH and enzymes 
                                          
The pharmacokinetic evaluation requires knowledge on a drug’s elimination 
half-life, total clearance, absolute bioavailability, possible first-pass effect and the 
desired steady concentrations for peak and trough. 
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Table 03: Pharmacokinetic parameters for drug selection. 
Parameter Comment 
Elimination half life Preferably between 0.5 and 8 h 
Total clearance Should not be dose dependent 
Elimination rate constant Required for design 
Apparent volume of distribution Vd 
The larger Vd and MEC, the larger will 
be the required dose size. 
Absolute bioavailability Should be 75% or more 
Intrinsic absorption rate Must be greater than release rate 
Therapeutic concentration Css av 
The lower Css av and smaller Vd, the 
loss among of drug required 
Toxic concentration 
Apart the values of MTC and MEC, 
safer the dosage form. Also suitable for 
drugs with very short half-life. 
 
1.4. MATRIX DIFFUSION CONTROLLED DRUG DELIVERY SYSTEM(28, 29, 30) 
In this type of controlled drug delivery system, the drug reservoir results from 
the homogeneous dispersion of the drug particles in either a lipophillic or a 
hydrophilic polymer matrix. 
Figure 01: Matrix diffusion controlled drug delivery system 
                               
 
Zone 1: Undissolved drug, glassy polymer layer. 
Zone 2: Undissolved drug, gel layer. 
Gel layer thickness = Difference between erosion and swelling front position. 
 
Zone 1 
Zone 2 
Zone 3 
Erosion front 
Swelling front 
Diffusion front 
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Figure 02: Mode of action of hydrophilic matrix dosage form         
  
1.5. MODE OF ACTION OF HYDROPHILIC MATRIX DOSAGE FORM30,31 
Hydrophilic matrix dosage forms essentially consist of a compressed blend of 
hydrophilic polymer and drug. 
According to the generally accepted mechanism, the drug release from 
hydrophilic matrix dosage forms starts when the tablet comes in contact with 
gastrointestinal fluid. The surface of the tablet hydrates to release exposed drug and at 
the same time form a viscous polymer mucilage or gel. This gel fills the interstices 
within the tablet, retarding further ingress of liquid. 
The concentration of polymer within the hydrated layer ranges from dilution at 
the outer surface to around 90% at the boundary with the drug core. Within this layer, 
drug in various states of dissolution (undissolved in dilute solution; in saturated 
solution) is distributed amongst the other ingredients of the tablets. 
Drug release occurs immediately from the surface (burst effect) followed by 
diffusion through, and / or erosion of, the hydrated layer. The relative proportions of 
drug released by diffusion and erosion are determined by the drug’s solubility 
Tablet erosion : 
Outer layer becomes fully 
hydrated, eventually dissolving into 
the gastric fluids. 
Water continues to permeate 
toward the tablet core. 
Gel layer 
Ingestion of tablet 
Initial wetting : 
Tablet surface wets and  
polymer begins to hydrate,  
forming a gel layer, initial  
burst release occur from the 
surface of the tablet. 
Expansion of the gel layer : 
Water permeates into the tablet, increasing 
the thickness of the gel layer, soluble drugs 
diffuse through the gel layer. 
Soluble drug: 
Is released primarily by 
diffusion through the 
gel layer. 
Insoluble drug : 
Is released primarily 
through tablet erosion. 
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properties and by the physical and chemical nature of the hydrated polymer. This in 
turn is influenced by other factors, including drug characteristics, dissolution medium 
and other, which continue to be investigated. 
1.6. BASIC KINETICS OF CONTROLLED DRUG DELIVERY13 
In order to establish a basis for discussion of the influence of drug properties 
and the route of administration on controlled drug delivery, following mechanisms 
need a fair mention,  
 Behavior of drug within its delivery systems  
 Behavior of the drug and its delivery system jointly in the body. 
The first of the two elements basically deal with the inherent properties of 
drug molecules, which influence its release from the delivery system.  For 
conventional systems, the rate-limiting step in drug availability is usually absorption 
of drug across a biological membrane such as the gastro intestinal wall. However, in 
sustained/controlled release product, the release of drug from the dosage form is the 
rate limiting instead, thus drug availability is controlled by the kinetics of drug release 
than absorption.   
1.6.1. Factors influencing the in vivo performance of sustained release dosage 
formulations32 
There are various factors that can influence the performance of a sustained 
release product. The physiological, biochemical and pharmacological factors listed 
below can complicate the evaluation of the suitability of a sustained release dosage 
formulation. 
Physiological : 
• Prolonged drug absorption 
• Variability in GI emptying and motility 
• Gastrointestinal blood flow 
• Influence of feeding on drug absorption 
Pharmacokinetic/ biochemical : 
• Dose dumping 
• First- pass metabolism 
• Variability in urinary pH; effect on drug elimination 
• Enzyme induction/ inhibition upon multiple dosing 
• Pharmacological 
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• Changes in drug effect upon multiple dosing 
• Sensitization/ tolerance 
1.6.2. Design and Fabrication of Oral CDDS33,34,35,36,37 
The majority of the oral controlled release systems are either tablets or 
capsules although a few liquid products are also available. Sustained release tablet 
and capsule dosage forms usually consist of two parts; an immediately available dose 
to establish the blood level quickly and a sustained part that contains several times the 
therapeutic dose for predicted drug levels. 
Several approaches are available to add the immediately available portion to 
the sustaining part. Simple addition of a non-sustained dose of drug to capsule or 
tablet is the most direct method; Placement of the initial dose in the tablet coat with 
the sustaining portion in the core represents an alternate approach.  
The majority of oral controlled release systems rely on dissolution, diffusion 
or a combination of both mechanisms, to generate slow release of drug to the gastro 
intestinal tract.  Starting with limited data on a drug candidate for sustained release, 
such as dose, rate constants for absorption and elimination, some elements of 
metabolism and some physical and chemical properties of the drug, one can estimate a 
desired release rate for the dosage form, the quantity of drug needed and a preliminary 
strategy for the dosage form to be utilized. 
1.6.3. In vitro evaluation of sustained release formulation :  
 The data is generated in a well-designed reproducible in-vitro test such as 
dissolution test. The method should be sensitive enough for discriminating any change 
in formulation parameters and lot-to-lot variations. The key elements for dissolution 
are : 
a) Reproducibility of method 
b) Proper choice of media  
c) Maintenance of sink conditions  
d) Control of solution hydrodynamics  
e) Dissolution rate as a function of pH ranging from pH 1 to 8 including several 
intermediate values preferably as topographic dissolution characterization.  
f) Selection of the most discriminating variables (media, pH rotation speed etc.) 
as the basis for dissolution test and specification. 
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Ideal in-vitro method can be utilized to characterize bio-availability of the 
sustained release product and can be relied upon to ensure lot-to-lot performance. 
1.6.4. Drug release mechanism from tablet matrices : 
    From time to time, various authors have proposed different types of drug 
release mechanism from matrices. It has been proposed that drug release from 
matrices usually implies water penetration in the matrix, hydration, swelling, 
diffusion of the dissolved drug (polymer hydro fusion), and/or the erosion of the 
gelatinous layer. Several kinetics models relating to the drug release from matrices are 
described below.12 
Zero-order kinetics38 
 
     W = k1 t 
                                    
First-order kinetics39 
 
      ln (100-W) = ln 100 – k2t   
        
Hixon-Crowel’s cube-root equation (erosion model)40 
 
                (100 – W) 1/3 = 1001/3 – k3t         
 
Higuchi’s square root of time equation (diffusion model)41 
 
     W = k4t1/2  
 
Korsmeyer et al equation (release model)    
 
                                                   Qt / Q∞ = K tn     
              
 Where W is percent drug release at time t and k1 to k4 are release rate 
constants, depending on the kinetic model used. The release mechanism of a drug 
would depend on the dosage form selected, pH, and nature of the drug and, of course, 
the polymer used. 
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1.7. Comparison of dissolution profiles : 
 Comparison of therapeutic performances of two medicinal products containing 
the same active substance is a critical means of assessing the possibility of alternative 
using between the innovator and any essentially similar medicinal product. 
The dissolution profile comparison may be carried out using model 
independent or model dependent method. A simple model independent approach uses 
a difference factor (f1) and a similarity factor (f2) to compare dissolution profiles. 
Matrix tablets for the last two decades have been popular in the formulation of 
controlled release. 
                                 St=1n(Rt-Tt) 
            f1 =                 x 100                                  
                                  St=1n Rt 
             
           f2 =  50 x log {[1+(1/n) St=1n(Rt – Tt) 2]-0.5 x 100}               
 
where Rt and Tt represent the average percent dissolved at time t for reference 
and test, respectively, and n is the number of time points tested. Dissolution profile 
was considered satisfactory if f1 values lies below 50 (nearing zero) and f2 value lies 
more than 50 (nearing 100). 
The model independent method is most suitable for dissolution profile 
comparison when three to four or more dissolution time points are available.42 
 
           Matrix tablets for the last two decades have been popular in the formulation of 
controlled release. 
 
Table 04 : Various drugs formulated as sustained release matrix tablets using 
different techniques 
Drug Technique Year 
Cefpodoxime43 Direct compression 2006 
Dextromethorphan Resinate44 Direct compression 2005 
Tramadolol HCl45 Direct compression 2005 
Zidovudine46 Wet granulation 2005 
Metformin HCl47, 48 Wet granulation 
Melt extrusion 
2004 
2005 
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As listed in Table 04, different methods are used to prepare matrix tablets i.e., 
dry blending (direct compression), wet granulation, melt granulation and extrusion 
spheronization. But in sustained release technology, directly compressed matrix 
tablets are the most attractive both scientifically and economically. 
 
 
 
 
Niacin49 Direct compression 2004 
Lithium carbonate50 Direct compression 2004 
Papaverine HCl51 Direct compression 2004 
Cefixime52 Wet granulation 2004 
Aspirin53, 54, 55 Direct compression 2003, 2001, 2000 
Metoclopramide HCl56 Melt dispersion 2002 
Ketoprofen57 Fluid bed granulation 2002 
Isosorbide dinitrate58 Direct compression 2001 
Prochlorperazine maleate59 Direct compression 2000 
Theophylline60 Direct compression 1998, 2002 
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2. LITERATURE REVIEW 

 Darshan, et.al., developed a matrix tablet with prochlorperazine maleate. In 
vitro studies were done using a USP-23 dissolution apparatus I at 100 rpm in 
simulated gastrointestinal fluid (first 2 hrs in 0.1 N HCL and phosphate buffer 
pH 6.8 subsequently). 

 Haider, et.al., developed a fatty based matrix tablets of metoclopramide HCl. 
The in vitro release was studied using USP dissolution apparatus type 1 at 50 
rpm. The dissolution media employed were 900 ml of 0.1 N HCl (pH-1.2) for 
the first hour, followed by medium of pH 4.5 for the next hour followed by 
medium of pH 7.5 for the remaining period of the experiment. 

 Paradkar, et.al., developed sustained release matrices of metformin HCl. The 
in vitro release was carried out in a USP 24 type II dissolution apparatus with 
a stirring rate of 100 rpm. Dissolution medium was 900 ml highly purified 
water maintained at 37+0.5oC. 

 Kale, et.al., developed matrix tablet of metformin HCl. the USP-23 
dissolution apparatus type I (basket) at rotation speed of 75 rpm was used for 
in vitro dissolution drug release testing. The dissolution medium consisted of 
900 ml of distilled water at 370.5oC. 

 Patel, et.al., developed matrix tablet of propranolol hydrochloride. The USP-
24 dissolution apparatus type I (basket) at rotation speed of 50 rpm, using 750 
ml of 0.1N HCl for the first 2 hours followed by 1000 ml of pH 6.8 buffer at 
37+0.5oC. 

 Reddy, et.al., developed once-daily sustained release tablets of nicorandil. 
The USP-24 dissolution apparatus type II at rotation speed 75 rpm. The 
dissolution medium consisted of 0.1N HCl for the first 2 hours and the 
phosphate buffer pH 7.4 from 3 to 24 hours (900ml), maintained at 37+0.5oC. 

 Emami, et.al., developed lithium carbonate matrix tablets. The USP-25 
dissolution apparatus type II (paddle) was used at rotational speed of 100 rpm. 
The dissolution medium consisted of 900 ml distilled water at 37 +0.5oC. 

 Baveja.S.K, et.al., (1986) studied release of liquid drug, Cetperazine from 
film coated and  uncoated matrix tablets using Eudragit RL and Eudragit 
RS. The release profile of tablets indicate that  if hydrophilic resins Eudragit 
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is present in the film, the release rate appears to be independent of the 
thickness of the film.67 

 Bhalla.H.L, et.al., (1987) compared release of Salbutamol from HPMC 
(Methocel K100M),  Ethylcellulose  and  its  combination  with  guar  gum.  
Formulations  showed appropriate  in  vitro  release  pattern  and  was  
evaluated  for  in  vivo  activity  and  had exhibited a sustained 
bronchodilatory effect.68 

 Bhalla. H.L, et.al., (1989) designed controlled release tablets and capsules 
of Ibuprofen by  using HPMC (K15M), Eudragit RL100 and Eudragit 
RS100 as release retardants.69 

 Bhalla.H.L, et.al., (1991) investigated the comparison of HPMC (K4M, 
K15M, K100M)  and  Eudragit  (RL100  and  RS100)  when  used  as  
polymeric  matrices  on Theophylline,  Salbutamol   Sulphate  and  
Ibuprofen  sustained  release  matrix  tablet formulations.11 

 Ford, et.al., (1991) described the influence of Sodium Lauryl Sulphate on 
the release of Propranolol Hydrochloride from HPMC matrix tablets and 
established phase of the ternary system.19 

 Wan.L.S, et.al., (1991) studied the effects of HPMC on aqueous penetration 
into matrices containing HPMC of varying viscosity and concentrations.20 

 Papadimitriou, et.al., (1993) explored the mechanism of swelling of 
Methocel K100 matrices, which gave the axial rather than the radial 
relaxation. Tablets of HPMC were investigated to determine whether the 
faces of cylindrical compacts of HPMC were of different nature to the 
edge.21 

 Kaul.D, et.al., (1994) designed the concept of dual control over the release 
of water soluble drug 1,2,dimethyl-3-hydroxypropyl-4-pyridone. Polymers 
used in matrix preparation include Eudragit (RLPM and RSPM).  

 Rangaiah.K.V, et.al., (1995) prepared sustained release tablets of 
Theophylline using Eudragit RLPO, RSPO and HPMC K15M and K100M. 
In addition water soluble and insoluble adjuvants were used to modify the 
release rate.23 
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
 Ruckmani.K, et.al., (1995) produced sustained release tablets of Nifedipine 
using Eudragit RS 100 and Eudragit RL 100, and obtained their in vitro 
dissolution profile.24 

 Cheng.H.L, et.al., (1995) prepared 5 controlled release matrices for 
Diclofenac Sodium by granulating 2 viscosity grades of HPMC in varying 
ratios with water in the planetary matrix.25 

 Katzhendler.I, et.al., (1997) developed a general mathematical model to 
describe drug  release  from  erodible  model  undergoing  surface  erosion.  
The  model  took  into account the three dimensions of the release kinetics by 
one or two erosion rate constants depending on the hydrodynamic conditions 
of the system.26 

 Pandey.V.P, et.al., (2003) formulated Diltiazem Hydrochloride as a 
sustained release matrix tablet using HPMC (Methocel-K4M), Ethylcellulose 
and Eudragit S 100 as sustaining material in various  proportions. Study 
indicates that higher hardness slowed the release pattern in dissolution 
study.7 

 Reddy.K.R, et.al., (2003) formulated the once-daily matrix tablet of 
Nicorandil using Ethylcellulose, Eudragit RL 100 Eudragit RS 100, 
Polyvinylpyrrolidone, HPMC, Sodium  carboxymethylcellulose and Sodium 
alginate. The results showed that HPMC alone could not control the release 
effectively for 24 hours.13 

 Vidyadhara.S, et.al., (2003) formulated and evaluated Propranolol 
Hydrochloride as  oral  controlled  release  matrix  tablets  using  hydrophilic  
polymer  such  as  HPMC (Methocel K4M) along with electrolytes. In this 
work an attempt was made for in situ interactions between drug and 
electrolytes to control the release of highly water soluble drugs from oral 
hydrophilic monolithic systems.28 

 Rao.B.S, et.al., (2004) utilized a simple technique to design and evaluate 
sintered matrix tablet for the controlled release of Rifampicin using 
Eudragit RL 100. Sintering technique compacted the mass further so the 
drug release is retarded and followed first- order release kinetics with 
diffusive mechanisms.29 
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
 Shirwaikar.A.A, et.al., (2004) designed sustained release tablets by utilizing 
the bilayer concept. Ethylcellulose and Rosin were used as the matrix forming 
materials. The formulation gave an initial burst effect followed by sustained 
release for 12 hours which indicates bimodal release of Diltiazem 
Hydrochloride from the matrix tablets.30 

 Shirwaikar.A.A, et.al., (2005) used Rosin as matrix forming material for 
studying the release  of  Diltiazem Hydrochloride. The release mechanism 
and the release rate kinetics of tablets were  examined using different 
release models. It was observed that with increase of the polymer content the 
release was retarded.31 

 Hayashi.T,  et.al., (2005) formulated the matrix tablets of Theophylline. In 
the study two  types  of tablets were prepared Tab. A of swelling-
disintegrating type using hydrophobic  wax  granules  and  Tab.  B  primarily  
composed  of  HPMC  (2910)  and Ethylcellulose.32 

 Kale.V.V, et.al., (2005) investigated the influence of surface area / volume 
on drug release  from sustained release matrix tablets containing Guar gum 
on Metformin Hydrochloride as a model drug. Drug release mechanism 
from Guar gum matrix tablets was also evaluated. Effect of increasing 
surface area / volume on release of the model drug was examined. Overall 
tablets with larger surface  area / volume values had slow release of drug, 
where as not much change in the release of drug was observed related to 
constant surface area by changing the tablet diameter.33 
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3.1. AIM AND OBJECTIVES 
The aim of the present investigation is to formulate and evaluate matrix tablets 
of cefixime using a mixture of polymers in view to sustain the drug release, reduce 
frequency of administration and improved patient compliance. 
 
The objectives of the research work undertaken are as follows: 
(a) To prepare sustained release matrix tablet of cefixime using different polymers.  
(b) To characterize developed tablets for hardness, thickness, weight variation, 
dimensions etc., 
(c) In vitro evaluation of matrix tablets by comparing with marketed products. 
 
In the present investigation, efforts were made to develop a sustained release 
formulation of cefixime for treatment of bacterial infection. The intended formulation 
was matrix tablet of cefixime, which will provide similar in vitro release profile to 
that of commercial marketed product.  
Cefixime is available as 200 mg tablets. It is also available as once daily 
preparation in the market and hence was a challenge to develop tablets using lesser 
amount of excipients and polymer, which will give advantage of cost reduction 
compared to the marketed product.52 
  The drug chosen for the present investigation is Cefixime, a cephalosporin, an 
orally active antibacterial agent. It is effective when given as a once-a-day dosing 
regimen for treating respiratory tract infection, urinary tract infection in children61, 
adults61-66 and otitis media in children.67 It is active against both gram-negative and 
gram-positive microorganisms. The acute toxicity of cefixime is comparatively low. It 
is stable to hydrolysis by many beta-lactamases.68 So, it is more appropriately referred 
to as bactericidal agent and found to be well-tolerated and safe on chronic use.  On 
oral administration, it is absorbed throughout GI tract and absolute bioavailability of 
cefixime is approximately 40- 50%.68 Cefixime has 65% binding with plasma 
proteins. About 20% of an oral dose (or 50% of an absorbed dose) is excreted 
unchanged in the urine within 24 hours and upto 60% may be eliminated by nonrenal 
mechanisms. It has a plasma elimination half-life of 3 to 4 hours. Its daily oral dose is 
0.2 to 0.4gm per day in two divided doses.  Recommended dosage of conventional 
tablets is 2 to 3 times a day.19 
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3.2. RATIONALE FOR DRUG SELECTION 
(a) Cefixime has a biological half-life of 3-4 hours and it requires to be 
administered two-times a day dosing.  In principle, drug candidate having 
biological half life 2 to 8 hours is suitable to be developed into sustained 
release dosage form. 
(b) As cefixime is a bactericidal agent, a minimum plasma concentration is 
necessary for a bactericidal activity. Thus, an oral sustained release 
preparation that can maintain effective concentrations for a prolonged period 
will be a suitable mode of administration. 
(c) Cefixime was proved effective when given as a once-a-day dosing regimen for 
treating otitis media in children and for respiratory and urinary tract infections 
in children and adults. 
(d) The pharmacokinetics of cefixime have previously been reported in healthy 
subjects showed that there were no changes in serum concentrations or urinary 
excretion of the drug over a 15days dosing period when given either as a 
400mg once-a-day or as a 200mg twice-a-day. 
(e) The adverse events associated with cefixime are like nausea, vomiting, skin 
rashes, dizziness and diarrhea. These adverse events may be partially avoided 
using sustained  release dosage form. 
       Thus, cefixime is a suitable drug for developing in to a sustained release 
dosage form. 
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4. PLAN OF WORK 
With the above aim and objective, the work was planned as follows : 
1. Reference product characterization. 
2. Preformulation study of active pharmaceutical ingredient (API) 
 Cefixime (API)powder characterization  
 Solubility studies op API at different ph media 
 Compatability studies of API with excipients. 
3. Formulation of Cefixime tablets by using various excipients. 
4. Evaluation Cefixime tablets 
• Hardness 
• Friability 
• Thickness 
• Weight variation 
• Content uniformity 
• Invitro Dissolution study 
• Drug Release Kinetics 
• Comparative studies with marketed product 
5. Selection of best formulation on the basis of invitro drug release. 
6. Stability studies. 
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5. DISEASE PROFILE 
5.1. TREATMENT OF INFECTIONS: 
Cefixime treats infections of the, 
• Ear: Otitis caused by Haemophilus influenzae, Moraxella catarrhalis and 
Streptococcus pyogenes. 
• Sinuses: Sinusitis. 
• Throat: Tonsillitis, pharyngitis caused by Streptococcus pyogenes. 
• Chest and lungs: Bronchitis, pneumonia caused by Streptococcus 
pneumoniae and Haemophilus influenzae. 
• It is also used to treat typhoid fever. 
 
5.2. MECHANISM OF ACTION OF DESTRUCTION OF BACTERIA: 
Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding 
proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the 
third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by 
bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefixime 
interferes with an autolysin inhibitor. 
Figure 03: Antibiotics Mechanism of action 
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Figure 04: Cefixime Mechanism of action 
 
 
5.3. MICROBIOLOGY: 
Gram-positive Organisms:  
• Streptococcus pneumonia 
• Streptococcus pyogenes  
Gram-negative Organisms:  
• Haemophilus influenzae (beta-lactamase positive & negative strains)             
• Moraxella (Branhamella) catarrhalis (beta-lactamase positive)  
• Escherichia coli  
• Proteus mirabilis  
• Neisseria gonorrhoeae (penicillinase & non-penicillinase-producing 
strains)  
      Cefixime has been shown to be active in vitro against most strains of the 
following Organisms: 
Gram-positive Organisms.  
• Streptococcus agalactiae  
Gram-negative Organisms.  
• Haemophilus parainfluenzae (beta-lactamase positive & negative strains)  
• Proteus vulgaris  
• Klebsiella pneumonia 
• Klebsiella oxytoca 
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6. DRUG PROFILE 
CEFIXIME 
Cefixime is an orally active antibiotic. It exhibits a broad spectrum of 
antibacterial activity with minimum inhibitory concentrations similar to or less than 
those for other oral cephalosporins against many gram-negative and gram-positive 
microorganisms. It is effective when given once-a-day dosing regimen for treating 
otitis media in children and for respiratory and urinary tract infections in children and 
adults.18 
Structure  
 
Chemical Name : 8-[[2-(2-amino-1,3-thiazol-4-yl)-2-
(carboxymethoxyimino)acetyl]amino]-4-
ethenyl-7-oxo-2-thia-6-azabicyclo[4.2.0]oct-4-
ene-5-carboxylic acid. 
Empirical Formula : C16H15N5 O7 S2 
Molecular Weight : 453.452 g/mol. 
Melting Point : 218 to 225oC. 
Category : Antibacterial. 
Dose : 0.2 to 0.4 g/day in two divided doses. 
Water solubility : 55.11 mg/L. 
Description : White to light yellow, crystalline, hygroscopic. 
Solubility       : Very slightly soluble in water and is free soluble in 70%  
                                           sorbitol and in octanol.                                                      
Storage     :       Store in a well-closed container. 
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Pharmacokinetics 
Absorption : 
It is a BCS class IV (poorly soluble- poorly permeable) drug. The absolute 
bioavailability of cefixime under fasting or fed conditions is approximately 40-50%, 
however, time to maximal absorption is increased approximately 0.8 hours when 
administered with food. It is absorbed from entire GI tract.70 
Distribution : 
The apparent volume of distribution (V1) of cefixime is 0.1 L/kg. It is widely 
distributed throughout the body and reaches therapeutic concentration in most tissues 
and body fluids, including synovial, pericardial, pleural, peritoneal, bile, sputum, 
urine, bone, myocardium, gall bladder, skin and soft tissue. 
Cefixime is 65% bound to plasma proteins, which are more than 90% protein 
bound. At usual doses of 400 mg cefixime is well tolerated and no serious drug-
related adverse effects were observed. The maximum serum concentration of cefixime 
following 400 mg oral dose was 3.85 + 0.3 µg/ml.41 The time to reach maximum 
serum concentration is 2 to 6 hours which is delayed with food. The multiple oral 
dosing with cefixime leads to unchanged (from the first dose) serum concentration 
profiles over a 15-day period, therefore, even if cefixime is dosed only once a day, 
serum concentrations of cefixime will persist for a large fraction of the dosing 
interval.66  Information on the distribution of cefixime in body tissues and fluids is 
limited. It crosses the placenta. Relatively high concentrations can be achieved in bile 
and urine.49 
Metabolism and elimination : 
 About 20% of an oral dose (or 50% of an absorbed dose) is excreted 
unchanged in the urine within 24 hours. Up to 60% may be eliminated by nonrenal 
mechanisms; there is no evidence of metabolism but some is probably excreted into 
the faeces from bile. It is not substantially removed by dialysis.52  
Mechanism of action : 
 Like all beta-lactam antibiotics, cefixime binds to specific penicillin-binding 
proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the 
third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by 
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bacterial cell wall autolytic enzymes such as autolysis; it is possible that cefixime 
interferes with an autolysin inhibitor.70  It has a bactericidal action. The acute toxicity 
of cefixime is negligibly low. Cefixime is stable to hydrolysis by many beta-
lactamases.52  Structurally, cefixime possesses a vinyl group in the 3 position which is 
unique among oral cephalosporins. The substitution at the 3 position and the 
introduction of 2-aminothiazol-4-4yl-(alpha-alkoximine) and amide side chain at the 7 
position of cephem nucleus results in a favorable pharmacokinetic profile (i.e., oral 
absorption) and improved stability of beta-lactamases enzymes.18 
Indications : 
Cefixime exhibits broad spectrum of antibacterial activity with minimum 
inhibitory concentrations similar to or less than those for other oral cephalosporins 
against many gram-negative and gram-positive microorganisms. 
Cefixime is indicated in the treatment of the following infections when caused 
by susceptible strains of the designated microorganisms : (1) Uncomplicated urinary 
tract infections caused by Escherichia coli and Proteus mirabilis, (2) Otitis media 
caused by Haemophilus influenzae (beta-lactamase positive and negative strains), 
Moraxella catarrhalis (most of which are beta-lactamase positive), and Salmonella 
pyogenes, (3) Pharyngitis and tonsillitis caused by Salmonella pyogenes, (4) Acute 
bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus 
pneumonia and Haemophilus influenzae (beta-lactamase positive and negative 
strains), and (5) Uncomplicated gonorrhea (cervical/urethral) caused by Niesseria 
gonorrhoeae.70 
Dosage and administration : 
 The dose of cefixime is 0.2-0.4gm per day, administered in two divided doses. 
It is commercially available in 200 mg and 400 mg conventional tablet and 400 mg 
extended release tablet. 
 In children elder than or equal to 6 months : 8 mg/kg/day divided every 12 to 
24 hours. In children above 50 kg or elder than or equal to 12 years and adults, the 
recommended dose of cefixime is 400 mg per day or divided every 12 to 24 hours.42  
This may be given as a 400 mg tablet daily or as 200 mg tablet two times a day.71 
 A minimum plasma concentration is necessary for a bactericidal activity. 
However, it is established that increasing the drug concentration above this base value 
does not correspondingly increase bactericidal activity although continuous infusion 
is preferable to periodic administration.52 
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 Cefixime have been previously been reported in healthy subjects after 
progressively increasing single doses of up to 400 mg and after multiple oral dosing 
of the drug given at a total daily dose of 400 mg for up to 15 days. Pharmacokinetic 
profile of cefixime was similar to all dose levels studied and there were no changes in 
serum concentrations of urinary excretion of the drug over a 15 day dosing period 
when given either as a 400 mg once-a-day dosing or as a 200 mg twice-a-day 
regimen.18 
 Cefixime is effective when given as a once-a-day dosing regimen for treating 
otitis media in children and for respiratory and urinary tract infections in children and 
adults19 and also in uncomplicated cervical/urethral gonorrhea.72 
Contraindications43 : 
1. Cefixime is contraindicated in patients with known allergy to the 
cephalosporin group of anbiotics. 
2. It is contraindicated with carbamazepine as cefixime may increase serum 
levels of carbamazepine 
3. It is contraindicated with furosemide which may be a possible additive to 
nephrotoxicity. 
4. It has contraindications with probenicid which may decrease the 
cephalosporin elimination. 
Adverse Effects71 : 
 The most commonly seen adverse reactions of tablet formulation were 
gastrointestinal events, which were reported in 30% of adult patients on either two 
times a day or four times a day regimen. 
 Clinically mild gastrointestinal side effects occurs in 20% of all patients, 
moderate events occurred in 9% of all patients and severe adverse reactions occurred 
in 2% of all patients. 
 Individual event rates include diarrhea 16%, loose or frequent stools 6%, 
abdominal pain 3%, nausea 7%, dyspepsia 3% and flatulence 4%. 
 Symptoms of overdose include blood in the urine, diarrhea, nausea, upper 
abdominal pain, and vomiting. 
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Table 05: Pharmacokinetic Parameters of Cefixime 
 
Bioavailability 40-50% 
Protein binding 65% (concentration independent) 
Half-life 3-4 hours 
Metabolism Hepatic. 
Urinary excretion Approximately 50% of the absorbed dose is excreted 
unchanged in the urine in 24 hours. 
Volume of distribution 0.1 liters/kg 
Excretion Renal and Bilary 
Peak concentration 3.7 mcg/L 
Peak time 3.7 hour 
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7. EXCIPIENTS PROFILE 
7.1 HYDROXYPROPYL METHYLCELLULOSE73 
Synonyms 
 Cellulose, hydroxypropyl methyl ether, HPMC, methocel, metolose, and 
pharmacoat 
Empirical Formula 
 HPMC is a partially o-methylated and o-(2-hydroxypropylated) cellulose. It is 
available in several grades, which vary in viscosity and extent of substitution. 
Molecular Weight 
 10,000 – 15,00,000 
Description 
 HPMC is an odorless and taste less, white or creamy white colored fibrous or 
granular powder. 
Functional Category 
 Coating agent, film-former, stabilizing agent, suspending agent, tablet binder, 
viscosity-increasing agent 
Applications in Pharmaceutical Formulation 
 HPMC is widely used in oral and topical pharmaceutical formulations. In oral 
product it is primarily used as a tablet binder, in film coating and as an extended 
release tablet matrix. Concentration of between 2-5% w/w may be used as a binder 
either in wet or in dry granulation process. High viscosity grades may be used to 
retard the release of water-soluble drug from a matrix. Lower viscosity grades are 
used in aqueous film coating while higher viscosity grades are used with organic 
solvents. 
Solubility 
 Soluble in cold water, forming a viscous colloidal solution, practically 
insoluble in chloroform, ethanol, and ether, but soluble in mixture of ethanol and 
dichloromethane, and mixture of methanol and dichloromethane. 
Stability and Storage Conditions 
 HPMC is a stable material although it is hygroscopic after drying. Solutions 
are stable between pH 3-11. Increasing temperature reduces the viscosity of solutions. 
It undergoes a reversible sol to gel transformation upon heating and cooling 
respectively. 
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 HPMC powder should be stored in a well-closed container, in a cool, dry 
place. 
Incompatibilities 
 It is incompatible with some oxidizing agent. Since it is nonionic, it will not 
complex with metallic salts and ionic organics to form insoluble precipitates. 
Safety 
It is generally regarded as a nontoxic and non-irritant material although 
excessive oral consumption may have a laxative effect. 
7.2. XANTHAN GUM73 
Synonyms 
Corn sugar gum, Keltrol, Merezan, Polysaccharide B-1459, Rhodigel 
Empirical Formula 
It is a high molecular weight polysaccharide gum. It contains D-glucose and 
D-mannose as the dominant hexose unit, along with D-glucuronic acid, and is 
prepared as the sodium, potassium, or calcium salt. 
Molecular Weight 
2 x 106 
Description 
 Xanthan gum occurs as a cream or white-colored, odorless, free flowing, fine 
powder. 
Functional Category 
 Stabilizing agent, suspending agent, viscosity increasing agent 
Applications in Pharmaceutical Formulation 
 Xanthan gum is widely used in oral and topical formulations, cosmetics, and 
foods as a suspending and stabilizing agent. It has also been used to prepare sustained 
release matrix tablets. 
Solubility 
 Practically insoluble in ethanol and ether. Soluble in cold or warm water. 
Stability and Storage Conditions 
 Xanthan gum is a stable material. Aqueous solutions are stable over a wide pH 
range (pH 3-12) and temperature between 10-60 °C. Solutions are also stable in the 
presence of enzymes, salts, acids and bases. 
The bulk material should be stored in a well-closed container in a cool, dry place. 
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Incompatibilities 
 Xanthan gum is an anionic material and is not usually compatible with 
cationic surfactants, polymers, and preservatives since precipitation occurs. It is 
compatible with most synthetic and natural viscosity increasing agents.  
Safety 
 Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics and food products and it is generally regarded as nontoxic and nonirritant at 
the levels employed as pharmaceutical excipients. 
7.3. CARBOPOL73 
Synonyms 
Carbomer, Acritamer, acrylic acid copolymer, carboxy polymethylene, 
polyacrylic acid, carboxyvinyl polymer  
Empirical Formula 
 Carbopols are synthetic high-molecular-weight polymers of acrylic acid that 
are crosslinked with ether allylsucrose or allyl ethers of pentaerythriol. They contain 
between 56% and 68% of carboxylic acid groups calculated on the dry basis. 
Molecular Weight 
7 x 105 to 4 x 109  
Description 
 Carbopols are white-colored, fluffy, acidic, hygroscopic powders with slight 
characteristic odor. 
Functional category 
Bioadhesive, emulsifying agent, release modifying agent, suspending agent, 
tablet binder, viscosity-increasing agent 
Applications in Pharmaceutical Formulation 
Carbopols are mainly used in liquid or semisolid pharmaceutical formulations 
as suspending or viscosity increasing agents. Formulations include creams, gels, and 
ointments for use in ophthalmic, rectal, and topical formulations. Different grades of 
carbopols are used in different formulations like suspensions, tablets, or sustained 
release tablet formulations. In tablet formulations, carbopols are used as dry or wet 
binders and as rate controlling excipients. 
Solubility 
 Soluble in water and, after neutralization, in ethanol (95%) and glycerin. 
Stability and Storage Conditions 
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 Carbopols are stable, hygroscopic materials that may be heated at 
temperatures below 104°C for up to 2 hours without affecting their thickening 
efficiency. However, exposure to excessive temperature can result in depolarization 
and reduced stability. Complete decomposition occurs with heating for 30 minutes at 
260°C. Dry powder forms of carbopol do not support the growth of molds and fungi. 
 Carbopol powder should be stored in an airtight, corrosion-resistant container 
in a cool, dry place. The use of glass, plastic, or resin-lined container is recommended 
for the storage of formulations containing carbopol. 
Incompatibilities 
Carbopol are discolored by resorcinol and are incompatible with phenol, 
cationic polymers, strong acids, and high levels of electrolytes. Trace levels of iron 
and other transition metals can catalytically degrade carbopol dispersions. 
Safety 
Carbopols are used extensively in nonparenteral products. Carbopols are 
generally regarded as essentially nontoxic and nonirritant material; there is no 
evidence in humans of hypersensitivity reactions to carbopol used topically. 
7.4. LACTOSE73 
Synonym  
Lactochem; Microtose; Milk sugar; Pharmatose; Tablettose; Zeparox. 
Chemical Name 
O-β-D-Galactopyranosyl- (1↔4)-α-D-glucopyransoe anhydrous.                           
Molecular Weight 
342.30 (anhydrous) 
360.31 (monohydrate) 
Category 
Tablet and capsule diluent and filler. 
Description 
White to off-white crystalline particles or powder. Lactose is odourless and 
slightly sweet tasting. 
Solubility 
Soluble in water, practically insoluble in ethanol, ether, chloroform. 
Stability and Storage Conditions 
Under humid conditions (80% relative humidity and above), mold growth may 
occur. Lactose may develop a brown coloration on storage, the reaction being 
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accelerated by warm, damp conditions. Lactose should be stored in a well-closed 
container in a cool, dry, place. 
Safety 
Adverse reactions to lactose are largely attributed to lactose intolerance, which 
occurs in persons with a deficiency of the intestinal enzyme lactose. 
 
7.5. MAGNESIUM STEARATE74 
Synonyms 
Magnesium octadecanoate; octadecanoic acid, magnesium salt, stearic acid, 
magnesium salt. 
Empirical Formula 
C36H70MgO4 
Molecular weight 
591.34 
Structural Formula  
CH3(CH2)16COO)2Mg 
 Functional Category 
Tablet and capsule lubricant. 
Applications 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.  
Description 
Magnesium stearate is a fine, white, precipitated or milled, impalpable powder 
of low bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to the touch and readily adheres to the skin. 
Stability and storage conditions 
Magnesium stearate is stable and should be stored in a well closed container in 
a cool, dry place.  
Incompatibilities 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salt. 
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7.6. TALC74 
Synonyms  
A talc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil star; powdered alc; purified French chalk; Purtac; soapstone; steatite; 
superiore. 
Empirical Formula  
Talc is a purified, hydrated, magnesium silicate, approximating to the formula 
Mg6(Si2o5)4(OH)4. It may contain small, variable amounts of aluminum silicate and 
iron. 
Functional Category 
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Applications 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent. It is widely used as dissolution retardant in the development of controlled-
release products. 
In topical preparations, talc is used as a dusting powder, although it should not 
be used to dust surgical gloves. Talc is natural material; it may therefore frequently 
contain microorganisms and should be sterilized when used as a dusting powder. Talc 
is additionally used to clarify liquids and is also used in cosmetics and food products, 
mainly for its lubricant properties.  
Description 
Talc is a very fine, white to grayish- white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Stability and storage conditions 
Talc is a stable material and may be sterilized by heating at 160oC for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. 
Talc should be stored in a well-closed container in a coo, dry place. 
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7.7.COLLOIDAL SILICON DIOXIDE (AEROSIL)73 
Synonyms 
Aerosil, Cab-o-sil, colloidal silica, fumed silica, light anhydrous silicic acid, 
silicic anhydride, silicon dioxide fumed.     
Empirical Formula - SiO2 
Molecular Weight - 60.08 
Description 
 It is blush white colored, odorless, tasteless, nongritty, amorphous powder. 
Functional Category 
 It is used as an adsorbent, anticaking agent, glidant, disintegrant, viscosity 
enhancer. 
Applications in Pharmaceutical Formulation 
 It is widely used in pharmaceuticals, cosmetics and foot products. Its small 
particle size and large specific surface area give it desirable flow characteristics to 
improve the flow properties of dry powders in a number of processes e.g tableting. It 
is also used to stabilize emulsions and as a thickening and suspending agent in gels 
and semisolid preparations. In aerosols, it is used to promote particulate suspension. It 
is used in 0.1 to 0.5 % of tablet weight as glidant. It is also used as tablet disintegrant 
as an adsorbent dispensing agent.  
Solubility 
 It is practically insoluble in organic solvents, water and acids, except 
hydrofluoric acid, soluble in hot solutions of alkali hydroxice. Forms a colloidal 
dispersion with water. 
Stability and Storage Conditions 
 It is hygroscopic, but adsorbs large quantities of water without liquefying. It is 
stored in a well closed container in a cool, dry place. 
Incompatibilities - It is incompatible with diethyl stillbesterol. 
Safety   - It is regarded as a non-toxic and non-irritant material. 
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8. MATERIALS AND INSTRUMENTS USED 
8.1. MATERIALS USED : 
Table 06: Material used in cefixime sustained release formulation 
Cefixime USP ACE Pharmaceuticals Pvt.Ltd., Hyderabad 
Carbopol 971 Noveon Chemicals, Bangalore 
Xanthan gum C.P. Kelco, U.K 
Hydroxypropyl methyl cellulose Colorcon India Pvt. Ltd., Mumbai 
Lactose (Pharmatose) FMC biopolymer, Mumbai 
Aerosil Dow Chemical Company, USA 
Magnesium stearate Komal Pharmaceuticals, Ahmedabad 
Hydrochloric acid Finar Reagents, Mumbai 
Sodium hydroxide S.D. Fines Chemicals, Mumbai 
Potassium dihydrogen 
orthophosphate 
S.D. Fines Chemicals, Mumbai 
 
Commercial marketed product : 
Cefi OD Khandelwal Laboratories Ltd., Mumbai 
 
 
  
MATERIALS AND INSTRUMENTS 
Department of Pharmaceutics Page 39 
8.2. INSTRUMENTS USED: 
Table 07: Instruments used in cefixime sustained release formulation 
Compression machine  Cadmach, Ahmedabad 
Digital weighing balance Contech, Mumbai 
Dissolution automated sampling system Electrolab, Mumbai 
Dissolution test system(model -08l) Electrolab, Mumbai 
Friabilator, EF- 2 (USP) Electrolab,  Mumbai 
Hardness tester, Monsanto Shital Scientific Industries, Ahmedabad 
Cenco moisture balance Sartorius, Switzerland 
pH –meter Lab India, Baroda 
Stability chamber Thermolab, Mumbai 
Tap density tester (USP) JEL , Ahmedabad 
Vernier calipers Mahr Instruments, Ahmedabad 
Double cone blender Dwarkesh Instruments, Junagadh 
Reposogram (for angle of repose) Enar Reposograph, Ahmedabad 
Sieve shaker Jayant Scientific Ltd., Ahmedabad 
Ultrasonicator Toshcon, Germany 
Sealer (for aluminum pouch sealing) Jayant Scientific Ltd., Ahmedabad 
UV Spectrophotometer (1700) SHIMADZU UV-1700 PC, Shimadzu 
Corporation, Japan 
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9. PREFORMULATION STUDIES : 
9.1 Physical characteristics: 
9.1.1. Flow properties:  
  The flow properties of powders are critical for an efficient tableting 
operation.  A good flow of powder or granulation to be compressed is necessary to 
assure efficient missing and acceptable weight uniformity for the compressed tablets.  
If a drug is identified at the pre formulation stage to be “poorly flowable”, the 
problem can be solved by selecting appropriate excipients.  In some cases, drug 
powders may have to be pre-compressed or granulated to improve their flow 
properties.  During pre formulation evaluation of drug substance, therefore, its 
flowability characteristic should be studied, especially when the anticipated dose of 
the drug is large. 
 
9.1.2. Angle of repose :  
The angle of repose of cefixime trihydrate and the tablet blend were 
determined by the funnel method (Reposogram). The accurately weighed drug or 
tablet blend was taken in a funnel. The height of the funnel was adjusted in such a 
way that the tip of the funnel just touches the apex of the heap of the powder. The 
powder was allowed to flow through the funnel freely onto the surface. The diameter 
of the powder cone was measured and angle of repose was calculated using the 
following equation 
 
         θ = tan-1   -11                 
 
where h and r are the height and radius of the powder cone, respectively. Flow 
properties for different values of angle of repose were given below 
Table 08: Comparison between angle of repose and flow property 
Angle of Repose Flow 
< 25 Excellent 
25 – 30 Good 
30 – 40 Passable (addition of 0.2% glidant required) 
> 40 Poor 
             
       
  h 
  r 
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9.1.3.Bulk density :  
Loose bulk density (LBD) and tapped bulk density (TBD) were determined. 
Cefixime was passed through 18-mesh sieve to break the clumps, if any.  Accurately 
weighed 50 g of the drug was placed in a 100 ml graduated measuring cylinder. Initial 
volume was observed. The cylinder was tapped initially 500 times from a distance of 
14 + 2 mm.  The tapped volume (Va) was measured to the nearest graduated unit.  The 
tapping was repeated additional 750 times.  Again the tap volume was measured to 
the nearest graduated unit. The same thing was done for powder blend of the tablet. 
The LBD and TBD were calculated in g per ml using following formulae, 
        LBD = weight of the powder/volume of the packing                          
        TBD = weight of the powder/tapped volume of the packing                     
9.1.4.Compressibility index :  
The compressibility of the powder was determined by the Carr’s 
compressibility index. 
                Carr’s index (%) = [(TBD – LBD) x 100]/TBD        
Table 09: Flow properties and corresponding Carr’s Index values 
Excellent <10 
Good 11 – 15 
Fair 16 – 20 
Possible 21 – 25 
Poor 26 – 31 
Very poor 32 – 37 
Very very poor >38 
        9.1.5.Hausner Ratio53 
The Hausner ratio of the powder was determined by the following equation. 
Hausner ratio = TBD / LBD      
Table 10: Flow Properties and Corresponding Hausner’s ratio 
Excellent 1.00 – 1.11 
Good 1.1 – 1.18 
Fair 1.19 – 1.25 
Possible 1.26 -1.34 
Very poor 1.35 -1.45 
Very very poor >1.60 
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9.1.6.POTENCY OF THE DRUG: 
The potency calculation for cefixime for preparing the tablet of 400 mg dose is 
done by following equation : 
Cefixime used in this study is in trihydrate form. The total moisture content of 
the drug is 11.28%. Therefore, the amount of cefixime trihydrate to be taken for 
single dose is calculated as follows:        
                  Percentage  Potency  =  Dose x 100 x 100 
                                                                 X (100 – Y) 
                       where, X = assay, Y = total moisture content                    
                     Percentage Potency  =     400 x 100 x 100 
                                                            95 (100 – 11.28)   
                                                    =     474.6 
Hence, 474.6 mg of cefixime trihydrate is taken which is equivalent to 400 mg 
of cefixime USP. 
9.1.7.Determination of melting point :  
Melting point was determined by taking small amount of Cefixime in a 
capillary tube closed at one end.  The capillary tube was placed in an electrically 
operated melting point apparatus and the temperature at which the drug melts was 
recorded. This was performed thrice and average value was noted. 
9.2.  Solution properties: 
9.2.1. pH of the solution 
 Weighed and transferred accurately about 1.0 g of sample in a 200 ml clean 
and dried beaker, dissolved in carbon dioxide free water and made up the volume to 
100 ml with same solvent, mixed. Read the pH of freshly prepared solution by using 
precalibrated pH meter. The results are shown in results and discussion. 
9.2.2.Solubility: 
A semi quantitative determination of the solubility was made by adding 
solvent in small incremental amount to a test tube containing fixed quantity of solute 
or vice versa.  After each addition, the system is vigorously shaken and examined 
visually for any undissolved solute particles.   The solubility are expressed in terms of 
ratio of solute and solvent. The results are shown in results and discussion. 
 
PREFORMULATION STUDIES 
Department of Pharmaceutics Page 43 
9.3.Drug-excipient compatibility studies49:  
In the preparation of film formulation, drug and polymer may interact as they 
are in close contact with each other, which could lead to the instability of drug. 
Preformulation studies regarding the drug-polymer interaction are therefore very 
critical in selecting appropriate polymers. FT-IR spectroscopy was employed to 
ascertain the compatibility between Cefixime and the selected polymers.  The pure 
drug and drug with excipient were scanned separately. 
 Procedure :  
Potassium bromide was mixed with drug and/or polymer in 9:1 ratio and the 
spectra were taken.  FT-IR spectrum of Cefixime was compared with FT-IR spectra of 
with polymer. Disappearance of Cefixime peaks or shifting of peak in any of the 
spectra was studied. 
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10. FORMULATION DEVELOPMENT 
 10.1. REFERENCE PRODUCT CHARACTERISATION : 
One marketed product was subjected to evaluation to determine diameter, 
thickness, weight and dissolution profile.  The values of these properties were shown 
in the Table 13. The dissolution profile of marketed tablet is shown in Table 14. 
 
Table 11 : Evaluation of the marketed product21 of cefixime 400 mg 
 
Table 12: Dissolution profile of Cefi OD in 0.1N HCl and phosphate buffer pH 7.2 
Sampling time (hrs) Cumulative percent drug release* AM ±  SD 
0 0 
1 16.7 ± 1.0 
2 24.7 ± 0.5 
4 39.3 ± 0.5 
6 44.4 ± 1.0 
8 54.0 ± 1.5 
12 68.6 ± 0.5 
16 82.3 ± 2.0 
20 93.6 ± 1.0 
24 99.2 ± 1.5 
*Each value was an average of six determinations 
 
 
Brand name Cefi OD21 
Manufacturer Khandelwal Laboratories Ltd.,Mumbai 
Thickness 4.5 ± 0.2 
Weight of the tablet 650 ± 5 mg 
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10.2. Operational concept of matrix tablet 
Before describing the formulation aspects of dosage form, it is necessary to 
understand the intended operational aspects of the dosage form. 
In a majority of cases, polymer in matrix tablet readily hydrates, absorbs water 
and swells to form a gelatinous network or barrier layer, which acts as a diffusion 
barrier to drug molecules. Some of the parameters like rate of water penetration and 
uptake, hydration speed and extent of swelling of the polymer may affect the release 
rate of the drug. 
 Polymer chain dissolution from the matrix surface involves two distinguish 
processes. The first step involves the disentanglement of individual molecules at the 
matrix surface, which depends on the rate of hydration. This occurs at a critical 
polymer concentration, which is called as the polymer disentanglement concentration. 
This polymer concentration depends on the properties of the polymer and solvent. The 
second step involves the transport of these molecules from the surface across an 
aqueous diffusion layer, adjacent to the matrix, to the bulk solution. In general all 
matrices showed a decrease of drug release as the polymer level was increased. Based 
on this consideration, suitable design of dosage form was attempted. 
10.2.1. Formulation of matrix tablet 
As described in the methodology chapter the matrix tablets were prepared by 
simple direct compression method. In this method, all the excipients and drug were 
geometrically mixed and that blend was directly used for compression. Different 
polymers were used in different concentrations to get good sustained release of drug. 
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10.2.2. MANUFACTURE OF CEFIXIME TABLETS USING HPMC OF 
DIFFERENT CONCENTRATIONS  
 
The direct compression technique was followed to manufacture the Cefixime 
tablets. Cefixime trihydrate was passed through 30-mesh sieve. HPMC K4M CR, 
HPMC K15M CR, HPMC K100M CR, lactose (Pharmatose), colloidal silicon dioxide 
(Aerosil), talc were passed through 40- mesh sieve. Required amount of drug as well 
as polymer and excipients were weighed and transferred into the double cone blender. 
The blend was mixed for at least 10 minutes by running the blender at 25 rpm.  The 
blend was then lubricated by required quantity of magnesium stearate (60-mesh 
sieve). 
 
Table 13 : Formulation of cefixime tablets using HPMC of different viscosities 
Ingredients F-I (K4) mg F-II (K15) mg F-III (K100) mg 
Drug* 474.6 474.6 474.6 
Pharmatose 53.4 53.4 53.4 
HPMC K4 96.0 --- --- 
HPMC K15 --- 96.0 --- 
HPMC K100 --- --- 96.0 
Colloidal Silicon 
Dioxide (Aerosil) 3.2 3.2 3.2 
Talc 6.4 6.4 6.4 
Magnesium 
Stearate 6.4 6.4 6.4 
Total weight 640.0 640.0 640.0 
 
*Drug = Cefixime trihydrate equivalent to cefixime USP 400 mg 
 
The powder blend was compressed on 16-station rotary press using SC 
capsule shaped punches.  Punches measuring 16.4 x 8mm were used for compression 
of the tablets. 
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10.2.3. MANUFACTURE OF CEFIXIME TABLETS USING COMBINATIONS 
OF HPMC OF DIFFERENT VISCOSITY GRADES 
 
 The direct compression technique was followed to manufacture the cefixime 
trihydrate tablets. In formulations F-IV, F-V and F-VI, three HPMC polymers were 
used in combinations in equal quantities as shown in Table 13. The procedure 
followed to manufacture tablets is similar as described above. 
 
Table 14: Formulations of cefixime tablets using combinations of HPMC of 
different viscosity grades 
Ingredients F-IV (mg) (K4+K15) 
F-V (mg) 
(K4+K100) 
F-VI (mg) 
(K15+K100) 
Drug* 474.6 474.6 474.6 
Pharmatose 53.4 53.4 53.4 
HPMC K4 48.0 48.0 --- 
HPMC K15 48.0 --- 48.0 
HPMCK100 --- 48.0 48.0 
Colloidal Silicon 
Dioxide (Aerosil) 3.2 3.2 3.2 
Talc 6.4 6.4 6.4 
Magnesium 
Stearate 6.4 6.4 6.4 
Total weight 640.0 640.0 640.0 
 
*Drug = Cefixime trihydrate equivalent to cefixime USP 400 mg 
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10.2.4. MANUFACTURE OF CEFIXIME TABLETS USING XANTHAN GUM 
AND CARBOPOL 971 
The cefixime matrix tablets were developed using Xanthan gum (F-VII, F-
VIII and F-IX) and Carbopol 971 (F-X, F-XI and F-XII) as shown in table 14 and 
table 15. Quantity of Xanthan gum was selected as 5%, 7.5%, 10% of the total weight 
of the tablet in F-VII, F-VIII and F-IX respectively. Similarly Carbopol 971 was tried 
in three different percentages (5%, 7.5% and 10%). 
 
Table 15 : Formulations of cefixime tablets using xanthan gum in different 
concentrations 
Ingredients F-VII  (mg)  5% F-VIII  (mg) 7.5% F-IX  (mg) 10% 
Drug* 474.6 474.6 474.6 
Pharmatose 117.4 101.4 85.4 
Xanthan gum 32 48 64.0 
Colloidal Silicon 
Dioxide (Aerosil) 
3.2 3.2 3.2 
Talc 6.4 6.4 6.4 
Magnesium Stearate 6.4 6.4 6.4 
Total weight 640.0 640.0 640.0 
*Drug = Cefixime trihydrate equivalent to cefixime USP 400 mg 
 
Table 16 : Formulations of cefixime tablets using carbopol 971in different 
concentrations 
Ingredients F-X  (mg)    5% F-XI  (mg)  7.5% F-XII  (mg)   10% 
Drug* 474.6 474.6 474.6 
Pharmatose 117.4 101.4 85.4 
Carbopol 971 32.0 48.0 64.0 
Colloidal Silicon 
Dioxide (Aerosil) 
3.2 3.2 3.2 
Talc 6.4 6.4 6.4 
Magnesium Stearate 6.4 6.4 6.4 
Total weight 640.0 640.0 640.0 
*Drug = Cefixime trihydrate equivalent to cefixime USP 400 mg 
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11. EVALUATION OF CEFIXIME TABLETS 
The tablets were evaluated for in process and finished product quality control 
tests i.e.,appearance, dimensions (diameter and thickness), weight variation, hardness, 
friability, assay and drug content.  
11.1.1. Appearance : The tablets were checked for presence of cracks, depressions, 
pinholes etc if any, uniformity of the colour and the polish of the tablet.  
11.1.2. Dimensions : Thickness and diameter of a tablet were measured using vernier 
calipers. These values were checked and used to adjust the initial stages of 
compression. 
11.2. Uniformity of weight (Weight variation test) :  
20 tablets were weighed individually.  Average weight was calculated from 
the total weight of all tablets.  The individual weights were compared with the 
average weight.  The percentage difference in the weight variation should be within 
the permissible limits (+ 5%). The percent deviation was calculated using the 
following formula.               
                                      Individual weight – Average weight 
   Percentage Deviation =                                                                     x 100         
            Average weight 
11.3. Hardness test :  
The hardness was tested using Monsanto tester. “Hardness factor”, the average 
of the six determinations, was determined and reported. The force is measured in 
kilograms. 
11.4. Friability test :  
Permitted friability limit is 1.0%. Roche friabilator was used to measure the 
friability of the tablets.  Ten tablets were weighed collectively and placed in the 
chamber of the friabilator.  In the friabilator, the tablets were exposed to rolling, 
resulting from free fall of tablets within the chamber of the friabilator. It was rotated 
at a rate of 25 rpm. After 100 rotations (4minutes), the tablets were taken out from the 
friabilator and intact tablets were again weighed collectively. The percent friability 
was determined using the following formula. 
                                                    (W1 – W2) 
                     Friability  =            x 100        (13) 
         W1 
where, W1 = weight of the tablet before test,  
            W2 = weight of the tablets after test. 
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11.5. Uniformity of content :  
Twenty uncoated tablets were selected randomly and average weight was 
calculated. Tablets were crushed in a mortar individually and accurately weighed 
amount of tablet triturate from each blend was taken. Then, samples were transferred 
to twenty different volumetric flasks and were diluted up to the mark with purified 
water.  The content was shaken well for sometime and kept for 30 minutes for 
dissolving of drug completely. The mixtures were filtered and appropriate dilutions 
were made.  The drug content in each tablet was estimated at λmax 288 nm against 
blank reference and reported.  
11.6. In vitro drug release :  
In vitro drug release of the samples was carried out using USP–type I 
dissolution apparatus (basket type). The dissolution medium, 900 ml of 0.1 N HCl 
was placed into the dissolution flask for first 2 hours followed by pH 7.2 potassium 
phosphate buffer from 3 to 24hrs maintaining the temperature of 37 + 0.5oC and rpm 
of 100.  One cefixime tablet was placed in each basket of dissolution apparatus.  The 
apparatus was allowed to run for 24 hours.  Samples measuring 10 ml were 
withdrawn after every 1, 2, 4, 6, 8, 12, 16, 20 and 24 hours using auto sampler. 
During sampling samples were filtered through 10 µm filter which was in inline with 
auto sampler. The fresh dissolution medium (37oC) was replaced every time with the 
same quantity of the sample. Collected samples were suitably diluted with dissolution 
medium and analyzed at 288 nm using dissolution medium as blank. The cumulative 
percentage drug release was calculated. 
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11.7. INFLUENCE OF DIFFERENT PARAMETERS ON DRUG RELEASE 
An attempt was made to know the drug release mechanism from tablets in 
different conditions.  The following tests were carried out. 
11.7.1 Effect of agitational intensity : 
It is necessary to check that the effect of agitational intensity on the drug 
release. To study the effect of agitational intensity (rpm) of the dissolution medium, 
Release study was carried out at rotational speeds of 50, 75 and 100. Cumulative 
percentage drug release was calculated. 
11.7.2. Effect of hardness of the tablet : 
It is necessary to see, whether the hardness of the tablet effects on the drug 
release or not. For this study, three types of tablets were prepared with same powder 
blend and having same physical parameters but different hardness i.e.,8 
kg/cm2(standard), less than 6 kg/cm2 (less hardness) and more than 10 kg/cm2 (high 
hardness). Release study was carried out using USP-type I dissolution apparatus 
(basket type) at rotational speeds of 100 and purified water as dissolution medium for 
all three types of tablets varying in hardness. 
11.7.3. Stability studies : 
The optimized tablets were packed in amber-colored bottle, which was tightly 
plugged with cotton and capped. It was then stored at 40°C / 75% RH for 4 weeks. 
The tablets were evaluated for hardness, drug content, dissolution study and compared 
with tablets evaluated immediately after manufacturing. 
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12. RESULTS AND DISCUSSION 
 
12.1.Preparation of buffers and reagents : 
 
Sodium hydroxide solution, 0.2 M : Eight grams of sodium hydroxide was 
dissolved in distilled water and diluted to1000 ml with distilled water. 
Potassium dihydrogen phosphate solution, 0.2 M : Potassium dihydrogen 
phosphate (27.218 g) was dissolved in distilled water and diluted to 1000 ml. 
Hydrochloric acid solution, 0.1 N : Concentrated hydrochloric (8.5 ml) acid was 
diluted with distilled water and volume was made up to 1000 ml with distilled water. pH 
(1.2) was adjusted with dilute hydrochloric acid. 
Phosphate buffer solution, pH 7.2 : Potassium dihydrogen phosphate, 50 ml of 
0.2 M, was placed in a 200 ml volumetric flask, 34.7 ml of 0.2 M sodium hydroxide was 
added and then volume was adjusted with distilled water up to 1000 ml. pH was adjusted 
to 7.2 with dilute sodium hydroxide. 
 
ANALYTICAL METHODS 
Preparation of cefixime standard stock solution (1000 µg/ml) in 0.1 N HCl solution : 
 A standard stock solution of cefixime trihydrate was prepared by dissolving 
accurately weighed 100 mg of cefixime in 0.1 N HCl solution in a 100 ml volumetric flask 
and the volume was made up to 100 ml with 0.1 N HCl solution to obtain a stock solution 
of 1000 µg/ml. 
Determination of analytical wavelength : 
From the standard stock solution, 0.5 ml was pippetted into 100 ml volumetric 
flask. The volume was made up to 100 ml with 0.1 N HCl solution. The resulting solution 
containing 20µg/ml was scanned between 200 and 400 nm. The λmax was found to be 288 
nm. λmax, 288 nm was considered as analytical wavelength. 
Calibration curve of cefixime trihydrate in 0.1 N HCl solution : 
Accurately weighed quantity of cefixime trihydrate (50 mg) was dissolved in little 
quantity of 0.1 N HCl solution and volume was made up to 100 ml. Appropriate aliquots 
were taken into different volumetric flasks and volume was made up to 50 ml with 0.1 N 
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HCl solution so as to get drug concentrations of 4, 8, 12, 16 and 20 µg/ml. The 
absorbencies of these drug solutions were estimated at λmax 288 nm. This procedure was 
performed in triplicate to validate the calibration curve. The data were given in Table 18. 
A calibration curve was constructed as shown in Figure 07. 
Preparation of cefixime standard stock solution (1000 µg/ml) in phosphate buffer 
solution, pH 7.2 : 
A standard stock solution of cefixime was prepared by dissolving accurately 
weighed 100mg of cefixime in phosphate buffer solution, pH 7.2 in 100 ml volumetric 
flask. The volume was made up to 100 ml with phosphate buffer solution, pH 7.2 to obtain 
a stock solution of 1000µg/ml. 
Determination of analytical wavelength : 
From the standard stock solution, 1 ml was pippetted into 100 ml volumetric flask. 
The volume was made up to 100 ml with phosphate buffer solution, pH 7.2. The resulting 
solution containing 10 µg/ml was scanned between 200 and 400 nm. The λmax was found 
to be 288 nm.  USP 26 specifies λmax  of  288. 
Accurately weighed quantity of cefixime trihydrate (50 mg) was dissolved in little 
quantity of phosphate buffer solution pH 7.2 and volume was made up to 100 ml. 
Appropriate aliquots were taken into different volumetric flasks and made up to 50 ml 
with phosphate buffer solution pH 7.2, so as to get drug concentrations of 4 to 20 µg/ml. 
The absorbencies of these drug solutions were estimated at λmax 288 nm. This procedure 
was performed in triplicate to validate the calibration curve. The data were given in Table 
19. A calibration curve was constructed as shown in Figure 08. 
Analytical Method : 
 Suitable analytical method was developed for cefixime trihydrate using UV 
spectroscopy and analytical wavelength of λ max 288 nm and 285 nm were identified in 
phosphate buffer solution pH 7.2, 0.1N hydrochloric acid solution respectively. 
Calibration curves were constructed in these media. The methods have shown good 
reproducibility. Beer-Lambert’s law was obeyed in the range of 4 to 20 µg/ml for both 
phosphate buffer pH 7.2 and 0.1 N HCl solutions respectively. 
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UV spectroscopy scanning of cefixime in 0.1 N HCl : 
UV spectrum of cefixime in 0.1 N HCl (Figure 05) shows that the drug has λmax of 
285 nm that is near to the reported value of 288 nm.75 
 
Figure 05 : UV spectrum of cefixime in 0.1 N HCl 
 
 
 
 
UV spectroscopy scanning of cefixime in phosphate buffer pH 7.2 : 
UV spectrum of cefixime in phosphate buffer pH 7.2 (Figure 06) shows that the 
drug had λmax of 288 nm that was exactly similar as reported. 
 
Figure 06: UV spectrum of cefixime in phosphate buffer 7.2 
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12.2. Standard curve of cefixime 
12.2.1.Standard plot of cefixime in 0.1 N HCl : 
The standard calibration curve of drug in 0.1 N HCl is depicted as Figure 07. The 
data of absorbance was shown in Table 18. The data has correlation coefficient of 0.9991 
and the equation of regressed line depicted as Equation below. 
Y = 0.0442 X + 0.006  
Table 18 : Standard curve of cefixime in 0.1 N HCl at 285 nm 
 
Concentration (µg/ml) 
Absorbance* 
AM ±  SD 
0 0.000 ± 0.000 
4 0.181 ± 0.001 
8 0.364 ± 0.003 
12 0.543 ± 0.001 
16 0.725 ± 0.004 
20 0.875± 0.002  
Each value is an average of three determinations. 
 
Figure 07 : Standard plot of cefixime in 0.1 N HCl 
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12.2.2.Standard plot of cefixime in phosphate buffer pH 7.2 : 
The standard calibration curve of drug in phosphate buffer pH 7.2 is depicted as 
Figure 08. The data of absorbance is shown in Table 19. The data had correlation 
coefficient of 0.9999 and the equation of regressed line depicted as Equation below. 
Y = 0.0376 X + 0.002 
Table 19 : Standard curve of cefixime in phosphate buffer pH 7.2 
at 288 nm 
 
Concentration 
(µg/ml) 
Absorbance* 
AM ±  SD 
0 0.000 ± 0.000 
4 0.153 ± 0.002 
8 0.307 ± 0.002 
12 0.457 ± 0.003 
16 0.606 ± 0.001 
20 0.752 ± 0.004 
*Each value is an average of three determination 
Figure 08 : Standard plot of cefixime in phosphate buffer pH 7.2 
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RESULTS AND DISCUSSION 
Matrix tablet was developed with a view to deliver the drug in a sustained manner. 
The details of results and discussion are given in the following sections. 
12.3. CHARACTERISATION  OF CEFIXIME TRIHYDRATE (API) POWDER : 
 The loose bulk density (LBD) of the drug was found to be 0.675 gm/cc. The tapped 
bulk density (TBD) of the drug was found to be 0.757 gm/cc. The angle of repose of 
cefixime trihydrate was 34. The Carr’s compressibility index was 12.56 i.e. less than 20. 
Therefore, to increase compressibility directly compressible excipients were added into the 
formulation. 
 
DRUG –EXCIPIENTS INTERACTION STUDY 
Fourier transform infrared spectroscopy (FTIR) : 
As described in the methodology section the fourier transform infrared 
spectroscopy studies were carried out for pure drug cefixime along with its physical 
mixture. The results are summarized as follows : 
Cefixime : 
IR spectra of pure cefixime and cefixime with physical mixture are shown in 
Figure 09 and Figure 10 respectively. 
An IR spectra of pure cefixime shows the following : 
A weak peak at 3295.10 cm -1 – Beta lactam ring. 
Another peak at 1336.31 cm-1 shows –C-N- stretch indicates primary aromatic 
amine group. 
The above two peaks can be considered as characteristic peaks of cefixime. These 
two peaks are prominently observed in case of IR spectra of cefixime along with 
excipients in its physical mixture as shown in Figure 10 and Table 20. 
 
RESULTS AND DISCUSSION 
Department of Pharmaceutics                                                                      Page 58 
Table 20 : Wave number of functional groups of cefixime along with excipients. 
Functional 
groups 
Pure cefixime 
(Figure 7) 
Cefixime + 
Xanthan gum 
(Figure 8) 
Primary 
aromatic amine 
group 
1336.31 cm-1 1336.75 cm-1 
Beta lactam 
ring 
3295.10 cm-1 3302.40 cm-1 
 
Therefore, perusal to Figure 09 and 10 indicates there is no interaction between 
cefixime and xanthan gum used in the formulation. Hence, xanthan gum was selected as 
release retardant agent.  
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Figure 09: FTIR of cefixime (pure) 
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12.4. Dose calculation for sustained release tablet of cefixime : 
Calculation of theoretical release profile of cefixime from sustained-release formulations. 
The total dose of cefixime for a once-daily sustained-release formulation was calculated by 
the following equation using available pharmacokinetic data. 
          DT = DIR (1+0.693 * t/t1/2) 
Where, 
 DT   = total dose of drug, 
 DIR  = dose of the immediate release part , 
      t = time (hours) during which the sustained release is desired (24 hours), 
 t1/2  = half-life of the drug(3 hours).  
    
DIR  = Css * Vd    =  3.95 * 6.5    =  61.2  ≅ 61 mg 
                                      F                 0.42 
                 ( Css , Vd  and F are obtained from the literature)                                   
                 Thus,      DT =  61 (1+0.693 * 24/ 3) 
                                DT =  399.2 mg  ≅ 400 mg 
According to theoretical release pattern, a once-daily cefixime sustained release 
formulation should release 61 mg in 1 hour and 14.7 mg every hour up to 24 hours. 
12.5.Theoretical release profile : 
The theoretical release profile calculation is important to evaluate the formulation with 
respect to release rates and to ascertain whether it releases the drug in a predetermined manner. 
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Table 21 : Dissolution profile of cefixime according to theoretical calculation 
Sampling time 
(hrs) 
Theoretical Percent 
drug release 
Cumulative percent 
drug release* AM ±  SD 
0 0 0 
1 18.8 16.7 
2 22.3 24.7 
4 29.4 39.3 
6 36.5 44.4 
8 43.5 54.0 
12 57.6 68.6 
16 71.8 82.3 
20 85.9 93.6 
24 100 99.2 
   
Figure 11 : Comparison of in vitro release of cefixime from marketed product and  
theoretical release profile. 
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Table 22 : Physical properties of the blend of tablet batches prepared with HPMC of 
different viscosity grades. 
Parameter F-I (K4) 
F-II 
(K15) 
F-III 
(K100) 
LBD, gm/cc 0.6758 0.6529 0.5132 
TBD, gm/cc 0.8040 0.7926 06321 
Angle of repose 19.24 21.54 20.32 
Compressibility, % 15.94 17.62 18.81 
  
After getting all physical properties of the blend satisfactory, tablets were prepared. 
Physical as well as drug release pattern was studied for each batch. Physical properties of these 
batches are shown in Table 22 and Table 23.  
Table 23 : Evaluation of the Matrix Tablets Prepared using HPMC of different viscosity 
grades 
Sr. No Parameters F-I F-II F-III 
1 Hardness, kg/cm2*
 
8 ± 0.2 8 ± 0.2 8 ± 0.2 
2 Friability, % ** 0.87 0.76 0.83 
3 Uniformity of weight,mg * 640 + 5 640 + 5 640 + 5 
4 Drug content, % ** 98 97 97 
5 Thickness, mm * 5.40 + 0.2 5.60 + 0.2 5.30 + 0.2 
6 Width, mm * 8.0 + 0.1 8.0 + 0.1 8.0 + 0.1 
7 Length, mm * 16.4 + 0.1 16.4 + 0.1 16.4 + 0.1 
 
*Each value was an average of six determinations. 
** Results of one batch. 
RESULTS AND DISCUSSION 
Department of Pharmaceutics                                                                      Page 64 
12.6. EVALUATION OF COMPRESSED TABLETS 
12.6.1. Uniformity of weight (Weight variation test) :  
This is an important in-process quality control test to be checked frequently (every half an 
hour). Corrections were made during the compression of tablets. Any variation in the weight of 
tablet (for any reason) leads to either under medication or overdose. So, every tablet in each batch 
should have a uniform weight. The results obtained from tablets of F-I to F-III were found to be 
640+5, which complies with in the limit for uniformity of weight. 
Table 24 : The weight variation tolerance for uncoated tablets. 
Average weight of tablets 
(mg) 
Maximum percentage 
difference allowed 
130 or less 10 
130-324 7.5 
More than 324 5 
 
12.6.2. Hardness test :  
Hardness (diametric crushing strength) is a force required to break a tablet across the 
diameter. The hardness of a tablet is an indication of its strength. The tablet should be stable to 
mechanical stress during handling and transportation. The degree of hardness varies with the 
different manufactures and with the different types of tablets. The results obtained from tablets of 
F-I to F-III showed hardness of 8 ± 0.2 which is same as desired. 
12.6.3. Friability test :  
Friability is the loss of weight of tablet in the container/package, due to removal of fine 
particles from the surface. This in-process quality control test is performed to ensure the ability of 
tablets to withstand the shocks during processing, handling, transportation and shipment. The 
results obtained from tablets of F-I, F-II and F-III showed the friability of 0.87, 0.76 and 0.83 
respectively which is under acceptable range. 
12.6.4. Content of active ingredient (Assay) :  
The amount of active ingredient(s) was determined and compared with standards stated in 
the monograph. Twenty tablets were used for assay. All the batches should fall with in the limit of 
95 – 105%. The assay results of tablets of F-I, F-II and F-III showed results of 98%, 97% and 99% 
respectively.  
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12.6.5. Dissolution profile of the matrix tablets prepared with HPMC of different viscosity 
grades :  
After getting all the physical parameters satisfactory for all the batches, dissolution of all 
batches were tested. Dissolution was carried out as mentioned in methodology chapter using 
dissolution USP type I apparatus.  
For F-I to F-III dissolution parameters and results of percent drug release is stated below in 
Table 25. 
Table 25  : In vitro release of cefixime from tablets of F-I to F-III 
Time of sampling 
in hours 
Cumulative percent drug release* 
AM ±  SD 
F-I F-II F-III 
0 0 0 0 
1 57 ± 1.0 53 ± 1.5 24.7 ± 0.5 
2 78 ± 1.5 69 ± 0.5 33.5 ± 1.5 
4 97 ± 2.0 87 ± 1.0 47.2 ± 1.0 
6 --- 98 ± 1.5 59.4 ± 1.0 
8 --- --- 64.6 ± 1.5 
12 --- --- 78.2 ± 2.0  
16 --- --- 87.4 ± 0.5 
20 --- --- 93.3 ± 0.5 
24 --- --- 99.6 ± 2.0 
                                  *Each value was an average of six determinations 
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Figure 12 : Comparison of in vitro release of cefixime from tablets of F-I(K4), F-II(K15) and 
F-III(K100). 
 
 
Drug release profile of F-III appeared to be closer to marketed product. The comparison of F-III 
with marketed product and theoretical release was shown in Figure 13. 
Figure 13 : Comparison of in vitro release of cefixime from tablets of F-III with 
marketed product and theoretical release profile. 
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Table 26 : Comparison factors of tablets of F-III with marketed product. 
Comparison with 
marketed product 
f2 value-  
Similarity factor 
f1 value- 
Dissimilarity factor 
Cefi OD 40.00 26.39 
Here physical properties of the tablets of all the batches were found satisfactory but the 
dissolution profile, percentage drug release were not satisfactory as compared to marketed product 
even in F-III (Table 21), where polymer viscosity was 1,00,000 cps. Hence, further combinations 
of different viscosity grades of HPMC were used. Two polymers of different viscosity grades 
were taken in 1:1 weight ratio. For example, 96 mg of HPMC K4 was replaced with 48 mg of 
HPMC K4 and 48 mg of HPMC K15. 
Table 27 : Physical properties of the blend of tablet batches prepared with combinations 
of  HPMC of different viscosity grades. 
Parameter F-IV F-V F-VI 
LBD, gm/cc 0.5418 0.5698 0.5246 
TBD, gm/cc 0.6946 0.7084 0.6785 
Angle of repose 19.54 22.19 20.53 
Compressibility, % 19.56 18.54 18.98 
After getting all physical properties of the blend satisfactory, tablets were prepared. Physical as 
well as drug release pattern was studied for each batch. 
Physical properties of these batches were shown in Table 27 and Table 28. 
Drug release pattern was shown in Table 29 and Figure 14. 
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Table 28 : Evaluation of the matrix tablets prepared with combinations of HPMC of 
different viscosity grades. 
SI. No Parameters F-IV F-V F-VI 
1 Hardness, kg/cm2 * 8 ± 0.2 8 ± 0.2 8 ± 0.2 
2 Friability, % ** 0.87 0.76 0.83 
3 Uniformity of weight, 
mg * 
640 + 5 640 + 5 640 + 5 
4 Drug content, % ** 98 99 98 
5 Thickness, mm * 5.42 + 0.2 5.45 + 0.2 5.51 + 0.2 
6 Width, mm * 8.0 + 0.1 8.0 + 0.1 8.0 + 0.1 
7 Length, mm * 16.4 + 0.1 16.4 + 0.1 16.4 + 0.1 
 
*Each value was an average of six determinations 
** Results of one batch 
12.6.6. Dissolution profile of the matrix tablets prepared with combinations of HPMC of 
different viscosity grades :  
  After getting all the physical parameters satisfactory for all the batches, dissolution of all 
batches was studied.  
For F-IV to F-VI dissolution parameters and results of percentage drug release is stated 
below in Table 29.    
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Table 29 :  In vitro release of cefixime from tablets of F-IV to F-VI 
Time of sampling in 
hours 
Cumulative percent drug release*  AM ±  SD 
F-IV F-V F-VI 
0 0 0  0 
1 48 ± 1.0  31 ± 0.5 20.5 ± 1.0 
2 67 ± 0.5 45 ± 1.5  37.5 ± 1.0 
4 87 ± 2.0  66 ± 1.5 50.9 ± 1.5 
6 98 ± 0.5 79 ± 0.5  63.2 ± 0.5 
8 --- 90 ± 2.0  71.9 ± 2.0 
12 --- 102 ± 1.5 84.4 ± 1.5 
16 --- ---  94.4 ± 0.5 
20 --- --- 100.2 ± 1.5 
24 --- --- 103.5 ± 2.0 
*Each value was an average of six determinations 
Figure 14: Comparison of in vitro release of cefixime from tablets of F-IV(K4+K15), F-
V(K4+K100) and F-VI(K15+K100).      
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 Table 30 : Comparison factors of tablets of F-VI with marketed product.  
 
 
 
 
 
Figure 15 : Comparison of in vitro release of cefixime from tablets of F-VI with 
marketed product and theoretical release profile. 
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K100M CR in different concentrations. 
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Table 31 : Formulations of cefixime tablets using HPMC K100M CR in different 
percentages. 
Ingredients F-VII  (mg)  12.5% F-VIII (mg) 17.5% 
Drug* 474.6 474.6 
Pharmatose 69.4 37.4 
HPMC K100 M CR 80.0 112.0 
Colloidal Silicon 
Dioxide (Aerosil) 
3.2 3.2 
Talc 6.4 6.4 
Magnesium Stearate 6.4 6.4 
Total weight 640.0 640.0 
 
*Drug = Cefixime trihydrate equivalent to cefixime USP 400 mg. 
 
Table 32 : Physical properties of the blend of tablet batches prepared with     HPMC 
K100M CR in different percentages. 
Parameter F-VII F-VIII 
LBD, gm/cc 0.5426 0.4540 
TBD, gm/cc 0.6487 0.5679 
Angle of repose 22.16 19.11 
Compressibility, % 18.98 20.02 
  
After getting all physical properties of the blend satisfactory, tablets were prepared. 
Physical as well as drug release pattern was studied for each batch. Physical properties of these 
batches were shown in Table 32 and Table 33. Drug release pattern was shown in Table 34 and 
Figure 16. 
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Table 33 : Evaluation of the matrix tablets prepared with HPMC K100M CR in different 
concentrations. 
SI. No Parameters F-VII F-VIII 
1 Hardness, kg/cm2 * 8 ± 0.2 8 ± 0.2 
2 Friability, % ** 0.82 0.81 
3 Uniformity of weight, mg * 640 + 5 640 + 5 
4 Drug content, % ** 99 98 
5 Thickness, mm * 5.9 + 0.2 5.9 + 0.2 
6 Width, mm * 8.0 + 0.1 8.0 + 0.1 
7 Length, mm * 16.4 + 0.1 16.4 + 0.1 
 
*Each value was an average of six determinations 
** Results of one batch. 
12.6.7. Dissolution profile of the matrix tablets prepared with HPMC K100M CR in 
different concentrations :  
After getting all the physical parameters satisfactory for all the batches, dissolution of all 
batches was studied.  
For F-VII and F-VIII dissolution parameters and results of percent drug release is stated 
below in Table 34 
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.Table 34 : In vitro release of cefixime from tablets of F-VII and F-V.  
Time of sampling 
in hours 
Cumulative percent drug release*  
 AM ±  SD 
F-VII F-VIII 
0 0 0 
1 51.9 ± 0.5 13.8 ± 1.5 
2 69.1 ± 1.5 20.2 ± 1.0 
4 85.7 ± 1.5  29.4 ± 2.0  
6 99.2 ± 1.0 37.2 ± 0.5  
8 109.6 ± 0.5  44.0 ± 1.0  
12 ---  55.1 ± 1.5 
16 --- 63.2 ± 2.0 
20 --- 69.7 ± 0.5 
24 --- 76.0 ± 1.0 
*Each value was an average of six determinations 
f1 and f2 values of F-III has been stated in Table 21.  
Figure 16 : Comparison of in vitro release of cefixime from tablets of F-VII (K100 12.5%), F-
VIII (K100 17.5%) and F-III (K100 15%). 
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Figure 17 : Comparison of in vitro release of cefixime from tablets of F-VIII 
with F-III and marketed product. 
                   
Here physical properties of the tablets of all the batches were found satisfactory but the 
dissolution profile, percentage drug release were not satisfactory as compared to marketed product 
even in F-VIII, where the concentration of HPMC K100 was 17.5%. Hence, further use of 
different HPMC was discontinued. 
Table 35 : Physical properties of the blend of tablet batches prepared with xanthan gum. 
Parameter F-IX F-X V-XI 
LBD, gm/cc 0.4497 0.4326 0.4849 
TBD, gm/cc 0.5579 0.5301 0.5874 
Angle of repose 20.32 21.78 22.14 
Compressibility, % 19.40 18.39 17.44 
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12.6.8. Physical properties of the blend of tablet batches prepared with xanthan gum : 
After getting all physical properties of the blend satisfactory, tablets were prepared. 
Physical as well as drug release pattern was studied for each batch. Physical properties of these 
batches were shown in Table 35 and Table 36. Drug release pattern was shown in Table 37 and 
Figure 18. 
Table 36 : Evaluation of matrix tablets prepared with xanthan gum. 
SI. No Parameters F-IX F-X V-XI 
1 Hardness, kg/cm2 * 8 ± 0.2 8 ± 0.2 8 ± 0.2 
2 Friability, % ** 0.76 0.87 0.82 
3 Uniformity of weight, mg * 640 + 5 640 + 5 640 + 5 
4 Drug content, % ** 96 99 98 
5 Thickness, mm * 5.9 + 0.2 5.9 + 0.2 5.9 + 0.2 
6 Width, mm * 8.0 + 0.1 8.0 + 0.1 8.0 + 0.1 
7 Length, mm * 16.4 + 0.1 16.4 + 0.1 16.4 + 0.1 
 
*Each value was an average of six determinations. 
** Results of one batch. 
12.6.9. Dissolution profile of the matrix tablets prepared with Xanthan Gum : After getting 
all the physical parameters satisfactory for all the batches, dissolution of all batches was studied. 
For F-VII to F-IX dissolution parameters and results of percentage drug release is stated below in 
Table 37. 
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Table 37 : In vitro release of cefixime from tablets of F-VII to F-IX. 
Time of sampling 
in hours 
Cumulative percent drug release* 
AM ±  SD 
F-IX F-X F-XI 
0 0 0 0  
1 52.8 ± 0.5 21.3 ± 1.5 8.1 ± 1.5 
2 69.5 ± 0.5 30.0 ± 1.5  17.4 ± 0.5 
4 94.3 ± 1.5 34.5 ± 0.5 22.7 ± 0.5 
6 109.8 ± 1.0  48.1 ± 1.0  27.7 ± 0.5 
8 --- 55.1 ± 2.0 31.2 ± 2.0  
12 --- 68.1 ± 2.0 39.0 ± 1.0  
16 --- 78.1 ± 1.5 45.3 ± 1.5 
20 --- 88.9 ± 1.0  51.8 ± 0.5 
24 --- 97.1 ± 1.5 58.6 ± 2.0 
*Each value was an average of six determinations. 
Here physical properties of the tablets of all the batches were found satisfactory but the 
dissolution profile, percentage drug release were not satisfactory in F-IX and F-XI. But in F-X 
percent drug release showed similarity with marketed product. Comparative drug release profiles 
were shown in Figure 18. f1 and f2 values were stated in Table 38. 
Figure 18 : Comparison of in vitro release of cefixime from tablets of F-IX (XG 5%), F-X 
(XG 7.5%) and F-XI (XG 10%). 
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Table 38 : Comparison factors of tablets of F-X with marketed product. 
Comparison with 
marketed product 
f2 value-  
Similarity factor 
f1 value- Dissimilarity factor 
Cefi OD 66.20 5.41 
 
Figure 19 : Comparison of in vitro release of cefixime from tablets of F-X with marketed 
product and theoretical release profile. 
 
This F-X, prepared using xanthan gum 7.5% gave good drug release profile and 
satisfactory similarity and dissimilarity factors in comparison with marketed product. 
This F-X can be taken as an optimized batch. 
Table 39 : Physical properties of the blend of tablet batches prepared with carbopol 971 
with different percentages. 
Parameter F-XII F-XII F-XIV 
LBD, mg/cc 0.4729 0.4885 0.4952 
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 After getting all physical properties of the blend satisfactory, tablets were prepared. 
Physical as well as drug release pattern was studied for each batch. Physical properties of these 
batches were shown in Table 39 and Table 40. Drug release pattern was shown in Table 41 and 
Figure 20. 
 
Table 40 : Evaluation of the matrix tablets prepared with carbopol 971 with different 
percentages. 
Sl. No. Parameters F-XII F-XIII F-XIV 
1 Hardness, kg/cm2 * 8 ± 0.2 8 ± 0.2 8 ± 0.2 
2 Friability, % ** 0.81 0.79 0.78 
3 Uniformity of weight, 
mg * 
640 + 5 640 + 5 640 + 5 
4 Drug content, % ** 98 98 97 
5 Thickness, mm * 5.42 + 0.2 5.41 + 0.2 5.44 + 0.2 
6 Width, mm * 8.0 + 0.1 8.0 + 0.1 8.0 + 0.1 
7 Length, mm * 16.4 + 0.1 16.4 + 0.1 16.4 + 0.1 
* Each value was an average of six determinations    ** Results of one batch 
12.6.10. Dissolution profile of the matrix tablets prepared with Carbopol 971 :  
After getting all the physical parameters satisfactory for all the batches, dissolution of all 
batches were tested. For F-XII to F-XIV results of percent drug release is stated below with its 
graphical representation. 
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Table 41 : In Vitro release of cefixime from tablets of F-XII to F-XIV. 
Time of sampling 
in hours 
Cumulative percent drug release* 
AM ±  SD 
F-XII F-XIII F-XIV 
0 0 0 0 
1 15.6 ± 0.5 11.8 ± 2.0 7.2 ± 1.0 
2 20.2 ± 1.5 17.3 ± 1.5 14.1 ± 1.5 
4 35.8 ± 0.5 32.4 ± 0.5 26.4 ± 2.0 
6 41.5 ± 2.0  37.3 ± 1.0  29.5 ± 1.0 
8 48.3 ± 2.0 44.2 ± 1.0 35.6 ± 1.0 
12 57.4 ± 1.5 52.7 ± 2.0 44.2 ± 1.0 
16 64.0 ± 0.5 59.3 ± 1.5 53.0 ± 2.0 
20 71.6 ± 0.5 66.1 ± 0.5  67.7 ± 0.5 
24 77.8 ± 2.0 72.8 ± 1.5 70.0 ± 0.5 
*Each value was an average of six determinations. 
Figure 20 : Comparison of in vitro release of cefixime from tablets of F-XII (CP 5%),F-XIII 
(CP 7.5%) and F-XIV (CP 10%). 
 
Comparative drug release profiles were shown in Figure 21. f1 and f2 values of F-XII with 
marketed product were stated in Table 42. 
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Figure 21 : Comparison of tablets of F-XII with marketed product and the 
theoretical release profile. 
 
Table 42 : Here, F-XIV shows good sustained release of drug but as per the result of  
dissimilarity factor still improvement in release profile was required so the use of carbopol 
971 was discontinued. 
Comparison with 
marketed product 
f2 value-  
Similarity factor 
f1 value- 
Dissimilarity factor 
Cefi OD 73.45 17.33 
Figure 22 : Comparison of in vitro release of cefixime from tablets of F-XIV with marketed 
product and theoretical release profile. 
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12.7. Optimization of the Batch : From all 14 batches of formulations prepared with different 
polymers in different percentages, F-X (Xanthan gum 7.5% of tablet weight) showed good drug 
release profile compared with marketed product. F-X also showed satisfactory similarity factor 
(f2= 66.20) and dissimilarity factor (f1= 5.41). Therefore, F-X was considered as optimized formula 
for preparation of cefixime sustained release matrix tablet using direct compression method. 
Further studies were carried on tablets of F-X.  
 Comparison of physical parameters and drug release profiles between F-X tablets and 
marketed product are shown in Table 43. 
Table 43 : Comparison of tablets of F-X with marketed product (Cefi OD). 
 Cefi OD F-X 
Thickness (mm) 4.5 ± 0.2 5.9 ± 0.2 
Weight (mg) 650 ± 5 mg 640 ± 5  mg 
Sampling time (hrs) 
Cumulative percent drug release* 
AM ±  SD  
0 0 0 
1 16.7 ± 1.0 21.3 ± 1.5 
2 24.7 ± 0.5 30.0 ± 1.5  
4 39.3 ± 0.5 34.5 ± 0.5 
6 44.4 ± 1.0 48.1 ± 1.0  
8 54.0 ± 1.5  55.1 ± 2.0 
12 68.6 ± 0.5 68.1 ± 2.0 
16 82.3 ± 2.0 78.1 ± 1.5 
20 93.6 ± 1.0 88.9 ± 1.0  
24 99.2 ± 1.5 97.1 ± 1.5 
Each value was an average of six determination 
RESULTS AND DISCUSSION 
Department of Pharmaceutics                                                                      Page 82 
 
Figure 23 : Comparison of tablets of F-X with marketed product (Cefi OD). 
 
Effect of different parameters on drug release :  
As discussed in methodology, the drug release profile in different conditions were 
compared with standard drug release profile, to check the effect of different parameters on drug 
release pattern. 
Effect of agitational intensity :  
In order to verify effect of agitational intensity of dissolution medium on drug release rate 
dissolution studies were conducted at three different rpm (50, 75, and 100).  Tablets of F-X were 
considered for this study. The release profile of drug from F-X tablets in different rpm and 
comparison is shown in Table 44 and in Figure 24. The cumulative percentage of cefixime 
released in 24 hours, were 85.9, 91.3, and 97.1 for 50, 75, and 100 rpm, respectively. A perusal to 
Figure 24 showed there was change in release profiles. This showed cefixime release from matrix 
tablet was dependent of agitational intensity. Therefore, it can be expected that as the rotational 
speed of the apparatus was increased, the integrity of the gel layer was decreased, and the release 
of drug was increased.  
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Table 44 : In vitro release of cefixime from F-X in different agitational intensity. 
Sampling time 
in hours 
Cumulative percent drug release*AM±SD 
50 rpm 75 rpm 100 rpm 
0 0 0  0 
1 17.2 ± 1.0 20.5 ± 1.5 21.3 ± 0.5 
2 26.6 ± 1.5 28.7 ± 0.5 30.0 ± 2.0 
4 29.3 ± 2.0 32.5 ± 2.0 34.5 ± 1.5 
6 42.3 ± 2.0 46.2 ± 0.5 48.1 ± 1.5 
8 50.1 ± 1.5 53.9 ± 1.5 55.1 ± 0.5 
12 63.6 ± 2.0 67.2 ± 1.0 68.1 ± 2.0  
16 74.4 ± 1.0 77.1 ± 1.0 79.1 ± 1.5 
20 81.1 ± 1.0 85.3 ± 1.5 88.9 ± 1.0 
24 85.9 ± 1.5 91.3 ± 2.0 97.1 ± 1.0 
*Each value was an average of six determinations. 
Figure 24: Comparison of in vitro release of cefixime from tablets of F-X at different 
rotational speeds. 
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Effect of hardness of the tablets : In order to verify effect of hardness on drug release dissolution 
studies were conducted on tablets having three different types of hardness (< 6 kg/cm2, 8 kg/cm2 
and > 10 kg/cm2). Other parameters of the tablets remain same. Tablets of F-X were considered 
for this study. 
Dissolution studies were carried out using USP dissolution apparatus I and results were 
shown in Table 45 and graph is plotted in the Figure 25. The cumulative percentage of cefixime 
released in 24 hours, were 98, 97.1, and 88.4% for tablets with 6,8 and 10kg/cm2 hardness 
respectively. 
When compared to tablets of 6 kg/cm2 hardness, dissolution profile of tablets of 8 kg/cm2 
was decreased. It could be because of decrease in porosity with increased hardness. Further 
increase in compressional force did not alter the release profiles. May be because of no significant 
change in porosity. 
As tablets with hardness of 8kg/cm2 were showing drug release profiles similar to that of 
marketed product, this hardness (8kg/cm2) was considered as ideal hardness. 
Table 45 : In vitro release of cefixime from F-X tablets of different hardness. 
Sampling 
time in hours 
Cumulative percent drug release* AM±SD 
< 6 kg/cm2 8 kg/cm2 > 10 kg/cm2 
0 0 0 0 
1 26.5 ± 1.5 21.3 ± 1.0 20.1 ± 1.0 
2 38.4 ± 1.0   30.0 ± 2.0 29.4 ± 1.0 
4 41.2 ± 1.5 34.5 ± 0.5 34.0 ± 1.5 
6 57.3 ± 0.5 48.1 ± 1.5 47.2 ± 2.0  
8 64.3 ± 1.5  55.1 ± 1.5 53.8 ± 1.0 
12 78.7 ± 2.0 68.1 ± 1.5 66.9 ± 1.5 
16 87.2 ± 2.0 79.1 ± 1.0 78.2 ± 1.5 
20 93.4 ± 1.5 88.9 ± 1.0 84.2 ± 1.0 
24 98.0 ± 1.0 97.1 ± 1.5 88.4 ± 1.0 
 
*Each value was an average of six determinations. 
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Figure 25 : Comparison of in vitro release of cefixime from tablets of F-X 
of different hardness. 
 
 
12.8. Kinetics of in vitro drug release 
Comparison of different orders for cefixime release : 
The release profiles of cefixime from tablets F-X was processed into graphs (Figure 26 to 
29) for comparison of different orders of drug release and, to understand the linear relationship, 
i.e., kinetic principles. 
The data were processed for regression analysis using MS-Excel statistical functions. 
 In vitro release data time points between 1 to 24 hours were considered and treated for 
following kinetic principles and values were shown in Table 46 and Table 47.  
Table 46:In Vitro release of cefixime from tablets of F-X 
Time (hrs) 
Cumulative 
percent 
drug released 
Percent drug 
remain 
Unreleased 
Log percent drug 
remain 
Unreleased 
0 0 100 2.0000 
1 21.3 78.7 1.8960 
2 30.0 70.0 1.8451 
4 34.5 65.5 1.8162 
6 48.1 51.9 1.7152 
0
20
40
60
80
100
120
0 4 8 12 16 20 24
Time (hours) 
Pe
rc
en
t d
ru
g 
re
le
a
se
 
< 6 
8 
> 10 
RESULTS AND DISCUSSION 
Department of Pharmaceutics                                                                      Page 86 
y = -3.4969x + 80.798
R2 = 0.9173
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24
Time (hrs)
Pe
rc
e
n
t d
ru
g 
u
n
re
le
a
se
d
y = -0.0443x + 1.9807
R2 = 0.9894
0
1
2
0 4 8 12 16 20 24
Time (hours)
Lo
g 
pe
rc
e
n
t d
ru
g 
u
n
re
le
a
s
e
d
8 55.1 44.9 1.6523 
12 68.1 31.9 1.5038 
16 79.1 20.9 1.3202 
20 88.9 11.1 1.0453 
24  97.1 3.87 0.8960 
 
Figure 26 : In vitro release profile of cefixime from tablets of F-X fitted in Zero order 
release. 
 
 
 
 
                      
 
 
 
 
 
Figure 27 : In vitro release profile of cefixime from tablets of F-X 
fitted in first order release. 
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Table 47 : Comparison of orders of in vitro release of cefixime from tablets of F-X 
Formulation 
In vitro release in 0.1N HCl and phosphate buffer pH 7.2 
Regression equations 
Zero order First order 
F-X 
y = - 3.4969 x + 80.798 
R2 = 0.9173 
Log y = -0.0443 x + 1.9807 
R2 = 0.9894 
 As shown in Figure 26, the formulation did not follow a zero-order release pattern. When 
data was plotted according to the first-order equation as shown in Figure 27, the formulation 
showed a fair linearity, with regression value of 0.9894. 
Release of the drug from a matrix tablet containing hydrophilic polymers generally 
involves factors of diffusion. In our experiments, in vitro release profiles of drug from all the 
formulation is expressed by Higuchi’s equation as shown in Figure 28. 
Figure 28 : In vitro release profile of cefixime from tablets of F-X 
fitted in Higuchi’s Plot 
 
                   In order to explore more precise mechanism of release of cefixime from in house 
developed matrix tablets, the dissolution data was also fitted to the well-known exponential 
equation (Korsmeyer equation), which is often used to describe the drug release behavior from 
polymeric system. 
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Figure 29 : In vitro release profile of cefixime from tablets of  
F-Xfitted in Korsmeyer equation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When plotted according to Korsmeyer et al76 equation, the formulation showed  R2 = 
0.9978 and slope (n) value of 0.4 (Figure 26). A value of n = 0.5 indicates case I (Fickian) 
diffusion or square root of time kinetics, 0.5<n<1 anomalous (non-Fickian) diffusion, n = 1 Case-
II transport and n > 1 Super Case-II transport. This n value is less than 0.5, hence, appears to 
indicate diffusion mechanism. The relative complexity of this formulation and its components 
may indicate that the drug release is controlled by diffusion process. 
Hence, diffusion may be the mechanism for the drug release from tablets of F-X. 
Reproducibility of release profiles : 
Batch to batch uniformity is very much essential for obtaining reproducible results.  In 
order to verify this fact, the manufacturing procedure was confirmed by preparing one more batch 
of the final optimized formulation of matrix tablets prepared with xanthan gum (F-X). The batch 
size was 1000 tablets. Release studies were conducted as specified for in vitro study and similar 
release profiles were obtained as shown in Figure 27 for tablets of F-X.   
The f1 and f2 values from model independent pair wise approach were found similar in the 
batches of tablets. The release pattern of the graphs demonstrated that the present manufacturing 
procedure offers reproducible results. 
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Table 48 : In Vitro release of cefixime from tablets of F-X of first and second (for 
confirmation of reproducibility) batches in 0.1N HCl and phosphate buffer pH 7.2. 
Sampling 
time in hours  
Percent drug release 
First trial Second trial 
0 0 0 
1 21.3 20.8 
2 30.0 32.6 
4 34.5 34.1 
6 48.1 48.9 
8 55.1 56.2 
12 68.1 67.9 
16 79.1 79.5 
20 88.9 88.4 
24 97.1 97.0 
 
Figure 30 : Invitro release of cefixime from tablets of F-X of first and second (reproducible) 
batches. 
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12.9. Accelerated stability study : 
Stability of a drug has been defined as the ability of a particular formulation, in a specific 
container, to remain with in its physical, chemical, therapeutic and toxicological specifications. 
 Matrix tablets of F-X (matrix tablet) were kept for accelerated stability study at  40 + 2oC 
and 75 + 5% RH for 1 month in the stability chamber.   
After a period of one month, the samples were observed for any change in physical 
parameters.  It was observed that surface was devoid of any change in color or appearance of any 
kind of spot on it.  It was also noted that surface was free of any kind of microbial or fungal 
growth or bad odor.  No changes in the smoothness of the tablets were noted.  The drug content of 
the formulations was found 98% for tablets of F-X, which shows that, there is no change in drug 
content and difference is insignificant.  The in vitro release of the samples after one month storage 
compared with release profile of sample at zero day and the same was shown in Table 49 for F-X 
(xanthan gum as matrix). Graphical representations were shown in Figure 31. 
Table 49 : In Vitro release of cefixime from tablets of F-X on zero day and  samples after 
one month accelerated stability studies. 
Sampling 
time in hours 
Tablets of 
zero day 
Tablets after 
one month 
0 0 0 
1 21.3 21.1 
2 30.0 29.4 
4 34.5 34.2 
6 48.1 47.7 
8 55.1 54.9 
12 68.1 67.8 
16 79.1 78.8 
20 88.9 88.6 
24 97.1 96.9 
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Figure 31 : In vitro release of cefixime tablets from F-X on zero day 
and after one month of accelerated stability studies 
                 
By comparison, it was found that after a period of one month of storage there were no 
changes in the physical as well as drug release profiles of the tablets of both the batches and both 
were imitating the same drug release pattern. The f1 and f2 values in the comparison of release 
before and after one-month storage (at accelerated conditions) were found 0.54 and 98.37 
respectively for matrix tablet (F-X).  
From the results and discussion, several conclusions were drawn and were given in the 
next chapter “Conclusions”. 
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SUMMARY 
Conventional dosage forms, which are prompt release in nature, have been used from 
decades for the treatment of acute and chronic diseases. To maintain drug concentration 
within the therapeutically effective range, it is necessary to take these types of dosage forms 
several times a day and which results in the fluctuations in drug levels.  Recently, several 
technical advancements have been made which results in new techniques for drug delivery. 
These techniques are capable of controlling the rate of drug delivery, sustaining the duration 
of therapeutic activity and/or targeting the delivery of drug to a tissue. Sustained release 
pharmaceutical dosage forms may offer one or more advantages over conventional 
(immediate release) dosage forms of the same drug. 
Sustained release dosage forms continue to draw attention in the search for improved 
patient compliance and decreased incidences of adverse drug reactions. Ideally, a sustained 
release dosage form will provide a therapeutic concentration of the drug in the blood that is 
maintained throughout the dosing interval with a reduction in a peak concentration ratio. One 
of the least complicated approaches is to form a tablet in which drug is embedded in matrix 
core of the polymer. Various types of polymers used as hydrophilic matrices and their 
modeling aspects have been reviewed. 
 
The objectives of the present investigation are: 
(a)   To prepare sustained release matrix tablet of cefixime using different polymers.  
(b) To characterize developed tablets for hardness, thickness, weight variation, dimensions, 
etc., 
(c)   In vitro evaluation of matrix tablets by comparing with marketed products. 
 
In the present investigation, efforts were made to develop an extended release 
formulation of cefixime for treatment many bacterial infections. The intended formulation 
will be matrix tablets of cefixime, which will provide similar in vitro release profile to that of 
marketed products which can be confirmed by calculating f1 (difference factor) and f2 
(similarity factor) values.   
 The chapter  “Literature Review” contained general concepts and requirements for 
sustained release drug delivery system. Classification, advantages and disadvantages of oral 
sustained release drug delivery systems, factors influencing the design of sustained release 
products, design and fabrication of matrix drug delivery systems were discussed. 
Development of matrix tablets was discussed in details. Different types of matrix sustained 
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release formulations were discussed with their principle of working. Extensive literature 
survey was done on simple matrix tablets for selection of polymer, excipients and method of 
manufacturing. Different methods for evaluation of performance of matrix system for 
independent of pH of media, and dependent on agitation intensity of releasing medium, 
hardness and surface area of the tablets were discussed. A detailed description about 
cefixime, polymer and excipients were discussed. 
      In order to solve the objectives of this dissertation, suitable analytical method (UV 
Spectroscopy) was established and validated in phosphate buffer solution pH 7.2 and in 0.1 N 
HCl. Physical properties of cefixime like loose bulk density, tapped bulk density, 
compressibility index and angle of repose were determined.  Tablet formulations for cefixime 
400mg matrix tablets were developed and were evaluated for pharmacopoeial and non-
pharmacopoeial (industry specified) tests. Polymer and concentration of polymer were 
optimized for matrix tablets. Tablets were prepared with different polymers like HPMC (K4, 
K15, K100), xanthan gum, carbopol in order to optimize one final formula for matrix tablets. 
Tablets were evaluated for physical and chemical properties. For matrix tablets in vitro 
release was carried out in 0.1 N HCl for first 2 hours followed by pH 7.2 phosphate buffer up 
to 24 hours using USP type I apparatus at 100 rpm. To study the effect of pH of medium on 
release in vitro, release studies were carried using pH change method and in phosphate 
buffer, pH 7.2. To study effect of agitational intensity of medium on release, in vitro release 
was conducted at different rpm (50, 75, and 100). To evaluate the effect of the physical 
properties of the tablets on release, in vitro release was conducted using different hardness 
tablets. Short-term accelerated stability study of optimized formulations of cefixime 400 mg 
matrix tablets were carried out at 40 ± 2oC and at 75 ± 5% RH for one month. 
The results and discussion of different methods of this thesis were described under 
different headings using graphs and tables.  No interference due to additives in the estimation 
of cefixime was observed (Figure 8).  Different polymers were used to get a suitable 
formulation of matrix tablets and finally were optimized to get optimized tablet formulations. 
The optimized formulation consists of xanthan gum (7.5% of total tablet weight). Tablets 
were evaluated for pharmacopoeial and nonpharmacopoeial (industry specified) tests and 
were found to be within the prescribed limits. Cefixime matrix tablets were prepared with 
different formulae for optimized formulations that show f1 and f2 in prescribed limits when 
using commercially available marketed sustained release products as reference standards.  
The average f1 and f2 values of optimized formulation were found to be 5.41 and 66.20 for 
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matrix tablets respectively.  The R2 = 0.9894 for the first order release (Figure 24) and for 
zero order release R2 = 0.9173 (Figure 23). Hence the release of cefixime from developed 
formulations was considered to be first order.  The drug release from the matrix tablets 
developed in this thesis was largely found to be independent of pH of medium.  The release 
was found to be highly dependent on the agitational intensity, and physical properties of the 
tablets like hardness. The Higuchi’s equation showed R2 = 0.9948 (Figure 25) and also when 
the data was fitted in to Korsmeyer et al equation it showed R2 = 0.9978 with slope (n) value 
of 0.4 (Figure 26) which is less than 0.5. Thus, diffusion of the drug was the main mechanism 
for drug release for the optimized formulation.  Manufacturing procedure was found to be 
reproducible and formulation was found to be stable for one month under accelerated stability 
condition. 
The conclusions drawn from the present investigation were given below 
 1.  Suitable analytical method based on UV-Visible spectrophotometer was developed 
for cefixime.  λmax of 288 nm and 285 nm was identified in phosphate buffer pH 6.8 
, and 0.1 N HCl solution respectively. 
2. Procedure to manufacture matrix tablets by direct compression was established. 
3.   Matrix tablets of cefixime (F-X) were successfully prepared using xanthan gum         
by direct compression method.   
4. The tablets were evaluated for pharmacopoeial and non-pharmacopoeial     (industry 
specified) tests.  Based on the results, F-X was identified as better     formulation 
amongst all formulations for matrix tablets. 
5.  Tablets of F-X passed all official and unofficial quality control tests. Drug release 
from the developed formulation follows first- order kinetics.  
6.   In vitro release profiles of optimized formulations of cefixime matrix tablets (F-X) 
was found to be similar to that of commercial marketed product. The average f1 and 
f2 values were found to be 5.41 and 66.20 for matrix tablets respectively. 
 
Thus, the objectives of the thesis are achieved. 
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14. CONCLUSION 
The conclusions drawn from the present investigation were given below : 
1. Suitable analytical method based on UV-Visible spectrophotometer was developed 
for cefixime.  λmax of 288 nm and 285 nm was identified in phosphate buffer pH 6.8 , 
and 0.1 N HCl solution, respectively. 
2. Procedure to manufacture matrix tablets by direct compression was established. 
3. Matrix tablets of cefixime (F-X) were successfully prepared using xanthan gum  by 
direct compression method. 
4. The tablets were evaluated for pharmacopoeial and non-pharmacopoeial (industry 
specified) tests.  Based on the results, F-X was identified as better formulation 
amongst all formulations for matrix tablets. 
5. Cefixime release from the developed matrix tablets has been observed to decrease at 
the amount of polymer increases in the tablets. 
6. Cefixime release from the matrix tablets was independent of pH of the dissolution 
medium, assuring the release to be fairly independent of pH of the GIT. 
7. Cefixime release from the matrix tablet was inversely proportional to the agitational 
intensity of the dissolution medium. 
8. Cefixime release from the matrix tablet was inversely proportional to the hardness of 
tablets, confirms physical properties of tablets contributes for mechanism for drug 
release. 
9. Tablets of F-X passed all official and unofficial quality control tests. Drug release 
from the developed formulation follows first- order kinetics. 
10. The manufacturing procedure was standardized and found to be reproducible. 
11. After one month accelerated stability developed formulations were found to be stable. 
12. In vitro release profiles of optimized formulations of cefixime matrix tablets (F-X) by 
using Xantham gum was found to be similar to that of commercial marketed product. 
The average f1 and f2 values were found to be 5.41 and 66.20 for matrix tablets 
respectively. 
The conclusions arrived in this thesis indicated that the sustained release formulations 
of cefixime trihydrate developed in this investigation was found to be equivalent to 
commercial market product, based on in vitro release studies.  Thus the objectives envisaged 
in this thesis were achieved. Further studies are needed to investigate these formulations for 
its performance in vivo and its bioequivalence with the available commercial products.  
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The conclusion arrived in this thesis indicate, that the sustained release oral dosage 
forms formulation containing Cefixime trihydrate designed, formulated and evaluated in this 
investigation was found to be equivalent to commercial market product in its composition. 
Thus the aim and objectives envisaged in this thesis were achieved. 
To achieve and to maintain the concentration of administered Cefixime sustained 
release drug within therapeutically effective range, and it is often necessary to reduce the 
intake of Cefixime drug dosage several times in a day and this result in a exact drug plasma 
levels. 
Further procedure to manufacture matrix tablets by direct compression was 
established in the form of documentation and performed. 
This technique for the drug administration is termed ‘sustained release’ or ‘controlled 
release’. It is based on the concept of implanting into the body, a reservoir of a drug 
contained in a special biodegradable polymeric carrier material.6  
The overall conclusion is that, once the drug/carrier material has been injected, or 
otherwise implanted or taken orally into the body, the drug is released at some predetermined 
rate for some desired period of time. 
In particular, the interest awakened by matrix type deliveries is completely justified in 
view of their biopharmaceutical and pharmacokinetics advantages over the conventional 
dosage forms. 
Further studies are needed to investigate these formulations for its performance in 
vivo and its bioequivalence with the available commercial products. 
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